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Summary 
Rheumatoid arthritis (RA) is a debilitating autoimmune disease of unknown etiology 
characterized by chronic joint inflammation accompanied by cartilage and bone 
destruction. Standard treatment regimens include disease-modifying medications like 
methotrexate, hydroxychloroquin, sulfasalazine and anti-TNF-α-therapy (American 
College of Rheumatology guidelines). New treatment strategies concentrate on the use of 
immunomodulatory agents such as the vasoactive intestinal peptide (VIP). VIP based 
treatment has shown to significantly reduce the incidence and severity of arthritis in 
animal models, abrogating joint swelling and destruction of cartilage and bone. The effect 
was associated with down regulation of both the inflammatory and autoimmune 
components of the disease.  
VIP is expressed in different primary immune organs (bone marrow and thymus) and also 
in the central and peripheral nervous systems. In the immune system, VIP acts as a 
chemotactic factor for T cells, and transduces expression of the matrix metalloproteinase 
MMP-9, thus facilitating T cell movement across basement membranes and other tissue 
structures. VIP binds with high-affinity to its two vasocative intestinal peptide receptors; 
VPAC1 and VPAC2.  
VPAC receptors are members of the G-protein coupled receptor (GPCR) –B family that 
also includes the receptors for the VIP related pituitary adenylyl cyclase-activating 
peptide (PACAP), secretin, glucagon, and calcitonin. Ligand binding activates these 
GPCR receptors, which stimulates adenylate cyclase activity and induces cyclic AMP 
(cAMP) increase. The VAPC2 receptor gene is encoded by 13 exons, the initiator codon 
of the 438 amino acid open reading frame is located in the exon 1, and the termination 
signal and a poly-adenylation signal sequence are found in exon 13. Other receptors 
belonging to this family are alternatively spliced, generating isoforms of the receptor.  
The central aim of this study was to identify and characterize murine VPAC2 splice 
variants. One splice variant, mVPAC2del_78, missing the first extracellular domain and the 
first transmembrane domain was identified in mouse lung tissue and further 
characterized. To this end, wildtype mVPAC1 and VPAC2del_78 cDNAs were cloned and 
expressed in Jurkat T cells. 125I-VIP receptor binding affinity was lower in mVPAC2del_78 
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compared to wildtype mVPAC1 transfectants. However, both mVPAC1 and 
mVPAC2del_78 transfectants showed an increase in intracellular cAMP concentration 
upon VIP or PACAP ligand binding, but mVPAC2del_78 was effective less than mVPAC1 
transfectants. MVPAC2del_78 transfectant survival was serum dependent, whereas 
wildtype mVPAC1 transfectants tolerated serum starvation. Interestingly, mVPAC2del_78 
transfectants showed less apoptosis compared to mVPAC1 and control pIRES 
transfectants. Both mVPAC1 and mVPAC2del_78 transfectants showed reduced migration 
rates compared to control transfectants upon VIP treatment.  This phenomenon was 
overridden by stromal derived factor-1 (SDF-1) treatment in mVPAC1 transfectants but 
not in mVPAC2del_78 transfectants. 
Conclusions: 
A new VPAC2 deletion variant was successfully isolated from mouse lung tissue. This 
deletion variant was examined regarding binding, apoptosis-signaling and migration. 
There were minor differences regarding binding to VIP between the VPAC transfectants, 
which so not appear to explain the different cAMP rise after stimulation. However, 
studies showed less apoptosis in mVPAC2 deletions variant as compared to mVPAC1 
transfectants. Migration studies showed no differences regarding the general migration of 
the VPAC transfectants; they both were effectively inhibited by VIP. 
More studies are necessary to examine the impact of these receptors during treatment of 
autoimmune diseases with VIP. 
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Zusammenfassung 
Die rheumatoide Arthritis ist eine Autoimmunerkrankung unklarer Ursache 
charakterisiert durch chronische, polyartikuläre Gelenkentzündungen begleitet in ca. 50% 
der Fälle von Knorpel- und Knochenzerstörung. Behandelt wird diese Erkrankung gemäß 
der Richtlinien 2008 des American College of Rheumatology mit 
erkrankungsmodifizierenden Antirheumamedikamenten wie Methotrexat, 
Hydoxychloroquin, Sulfasazalin und TNF-α-Blockern. Eine neue Therapiestrategie 
konzentriert sich auf die Verwendung von vasoaktivem intestinalem Peptid (VIP). Die 
Behandlung mit VIP reduzierte signifikant das Auftreten und den Schweregrad der 
Arthritis im Tiermodell und verhindert die Zerstörung von Knorpel und Knochen. Der 
Effekt war assoziiert mit der Runterregulierung der Entzündung und von Komponenten 
der Autoimmunität bei der Erkrankung.  
VIP ist ein chemotaktischer Stimulus für T- Zellen, einerseits modifiziert die Expression 
von Matrixmetalloproteinasen (MMP-9), andererseits erleichtert es die Migration der T-
Zellen durch die Basalmembran  und andere Gewebe. Vasoaktives intestinales peptide 
(VIP)  and  pituitary adenylate cyclase-aktivierendes Polypeptid (PACAP) sind 
bedeutende intrazelluläre Botenstoffe sowohl im zentralen als auch im peripheren 
Nervensystem und darüber hinaus in einer Vielfalt von nicht neuronalen Geweben. VIP 
ist ein wirksamer Neurotransmitter  mit verschiedenen physiologischen Funktionen, der 
in vielen Geweben exprimiert wird, primäre Immunorgane eingeschlossen. VIP bindet 
mit hoher Affinität an VPAC1- und VPAC2-Rezeptoren während das zugehörige 
pituitary adenylate cyclase-aktivierendes Polypeptide (PACAP) mit geringerer Affinität 
an die gleichen Rezeptoren und mit hoher Affinität an den PAC1 Rezeptor bindet. Diese 
Rezeptoren sind Mitglieder der G-Protein gekoppelten Rezeptoren (GPCR-) -B Familie, 
welche auch die Rezeptoren für PACAP, Secretin, Glucagon und Calcitonin beinhaltet. 
Die Adenylatcyclase Aktivität wird durch die Rezeptoren der GPCR-B Familie stimuliert 
mit einem konsekutiven Anstieg des zyklischen AMP (Adenosine monophosphat). Das 
VPAC2 Rezeptorgen ist auf dem Exon 13 kodiert, das Initiatorkodon des 438 
Aminosäuren offenen Leserahmen ist auf Exon 1 lokalisiert, das Beendigungssignal und 
die Polyadenylationssignal Sequenz ist lokalisiert auf Exon 13. Andere zu dieser Familie 
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gehörende Rezeptoren sind alternativ gespleißt um verschiedene Isoformen zu bilden. Es 
ist bis dato noch keine Isoform des VPAC2 Rezeptors in der Literatur beschrieben. 
Das Ziel dieser Studie war es, die Biologie des VPAC2 Rezeptors zu verstehen und eine 
gefunden Deletionsvariante des VPAC2 Rezeptors (mVPAC2del_78 ) der Maus zu 
beschreiben. 
 
Methoden: Der Maus-Deletionsvariante mVPAC2del_78  identifiziert aus dem 
Mauslungengewebe fehlen die Aminosäuren 115-138; die Variante erstreckt sich von der 
ersten extrazellulären Domäne bis zum ersten Teil der Transmembranendomäne.  Die 
vorliegende Arbeit etabliert die Existenz dieser neuen Splicevariante (26 Aminosäuren 
fehlend) und beschreibt ihre funktionellen Eigenschaften  im Hinblick auf Bindung, 
Aktivität der Adenylate cyclase (erhöhtes cAMP), Apoptose und Migration. Um diese 
Splicevariante weiter zu untersuchen, klonierten wir den Wiltyp des VPAC1-Rezeptors, 
die Deletionsvariante des VAPC2-Rezeptors (mVPAC2del_78 ) der Maus in 
vergleichbaren Konzentrationen in humane Jurkat T-Zellen und als Kontrolle den pIRES 
(primary internal ribosomal entry side) Vektor alleine ohne Rezeptor. 
 
Ergebnisse: Maus VPAC1 transfizierte Jurkat T Zellen banden 125I-markiertes VIP mit 
hoher Affinität. Es wurde von mVPAC2del_78  transfizierten mit geringerer Affinität 
gebunden und die Kontroll-transfizierten wurden gar nicht gebunden. Maus VPAC1 
transfizierte und zu einem geringeren Ausmaß mVPAC2del_78  transfizierte Jurkat T 
Zellen zeigten eine VIP oder PACAP-38 ausgelöste Erhöhung von intrazellulärem cAMP 
und eine minimale Erhöhung in den Kontroll-transfizierten. In Serumentzug-
Überlebensstudien (serum starvation) zeigten mVPAC2del_78 transfizierte und Kontroll- 
transfizierte Jurkat T Zellen eine Serumabhängigkeit, dagegen demonstrierten mVPAC1 
transfizierte eine Serumunabhängigkeit. In Apoptosestudien zeigte mVPAC2del_78  
geringere Apoptose als mVPAC1 und Kontroll-transfizierte Jurkat T Zellen. 
Migrationsstudien zeigten, dass VIP eine signifikante Reduzierung der Zellmigration in 
mVPAC2del_78  und mVPAC1 transfizierten Jurkat T Zellen verursachten, aber nicht in 
den Kontroll transfizierten. VIP Behandlung auf human stromal derived factor 
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vorbehandelte Zellen hemmte signifikant die Zellmigration von mVPAC1 und Kontroll 
transfizierten, aber nicht von mVPAC2del_78 transfizierten  Jurkat T Zellen. 
 
Schlussfolgerung: Es wurde eine neue VPAC2 Deletionsvariante (mVPAC2del_78 ) von 
Maus-Lungengewebe erfolgreich isoliert. Diese mVPAC2del_78 Deletionsvariante wurde 
hinsichtlich ihres Bindungs-, Apoptose-Signals und Migrationsverhaltens untersucht. 
Bezüglich Bindung an VIP war ein kleiner Unterschied zwischen den VPAC 
transfizierten Zellen erkennbar, welches die Abweichungen in dem cAMP Anstieg nach 
Stimulierung erklären könnte. In der cAMP Signaltransduktion demonstrierte die 
mVPAC2del_78 Deletionsvariante einen geringen cAMP Anstieg. 
Die Apoptoseuntersuchungen weisen bei mVPAC2del_78  Deletionsvariante eine geringere 
Apoptoserate auf als mVPAC1 transfizierte Jurkat T Zellen. 
In den Migrationstudien besteht kein signifikanter Unterschied hinsichtlich des 
Migrationsverhalten der VPAC transfizierten Zellen, sie stellen beide ein gehemmtes 
Migrationsverhalten hinsichtlich VIP dar. 
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1. Introduction 
1.1 General introduction 
In this thesis the functional role of vasoactive intestinal peptide (VIP) receptors in 
transfected Jurkat T-cells was examined. VIP receptors are members of the G-protein-
coupled receptors class II that use vasoactive intestinal peptide (VIP) as ligand (Segre et 
al., 1992). In immunity, VIP acts as a neuroimmunomodulator affecting various immune 
responses. The results of in vitro studies initially directed attention toward subsets of B 
cells and T cells, which express G-protein coupled receptors for VIP. The first published 
VIP actions were on T cells and dealt with enhanced adhesion and migration, decreased 
activation-induced apoptosis, altered generation of diverse cytokines and modified 
regulation of T cell-dependent B cell production of several immunoglobulins (Goetzl et 
al., 1995b). 
 
1.2 G-Protein-coupled Receptors 
The function of a cell is dictated in large part by carefully regulated networks of 
biochemical processes. Cells use signal transfer instruments (surface receptors) to 
exchange information with their environment. Receptors transmit signals intracellular by 
activating intracellular signalling pathways.  Many different classes of membrane-bound 
receptors exist including; ionotrop receptors, transmembrane receptors with enzyme 
activity, and the largest family, the G-protein coupled receptors. 
G-protein-coupled receptors (GPCR`s), also known as seven transmembrane domain 
receptors, comprise a superfamily with more than 1000 different members identified 
(Kolakowski, 1994). Many different ligands exist for these receptors including; amines, 
lipids, peptides, nucleotides, glycoproteins, proteases and ions (Kolakowski, 1994). 
Historically, GPCR`s have been classified into six subfamilies which were thought to be 
unrelated; three of these are found in vertebrates (Kolakowski, 1994). 
The three vertebrate families are the rhodopsin family (A), the secretin-receptor family 
(B), and the metabotropic glutamate receptor family (C).  
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GPCRs are thought to have a similar molecular architecture consisting of seven α-helical 
transmembrane domains (7TM), three extracellular loops (EC1, EC2, and EC3), three 
intracellular loops (IC1, IC2, and IC3), an amino-terminal extracellular domain and an 
intracellular carboxyl terminus. GPCRs can exist in active or inactive forms, where the 
inactive forms are favored. Some GPCRs exhibit constitutive activity under normal 
circumstances as in absence of the respective activating ligands (Holst and Schwartz, 
2003; Parnot et al., 2002). The study of chimeric and mutated GPCRs have demonstrated 
that the second (IC2) and third intracellular (IC3) loops, and to a lesser extent the 
proximal part of the carboxyl terminal tail, can be directly involved in G-protein/receptor 
interactions (Wess, 1997). 
 
Figure 1:   G-Protein-coupled Receptor 
 
 
 
 
 
 
     
1 2 4 3 5 6 7 
NH2 
COOH intracellular 
extracellular 
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Upon ligand activation, GPCR`s associate with distinct classes of heterotrimeric G 
proteins composed of three subunits, the α-subunit that has the guanine-nucleotide 
binding site and GTPase activity, and the β- and γ-subunits that form tightly bound 
dimer. The subunits of G proteins show a wide range of heterogeneity. There are more 
than 20 different mammalian Gα subunits and 5 β and 14 γ subtypes known, which are 
found in nature in many possible combinations (Radhika and Dhanasekaran, 2001). 
Stimulation of the G proteins subfamily activates adenlylyl cyclase, whereas stimulation 
of the Gi subfamily leads to the inhibition of the adenlylyl cyclase and activates K+ 
channels. Stimulation of the Gq subfamily activates phospholipase C (PLC), and the G12 
family is implicated in the regulation of small GTP binding proteins. 
Within the superfamily of G protein-coupled receptors, there has emerged during the past 
few years a subfamily that shares the seven membrane-spanning domain topography, but 
has a low overall amino acid sequence homology (<20%) with other members of the 
superfamily. It is now referred to as the class II G protein-coupled receptor family and 
comprises receptors for a structural family of peptides that includes VIP, PACAP 
glucagon, secretin, glucagon-like peptide 1, gastric inhibitory polypeptide, growth 
hormone-releasing factor and receptors for parathyroid hormone and calctonin (Nicole et 
al., 1998).  
In many cases, these G proteins can couple to more than one receptor subtype, with 
different affinities. 
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Activates phospholipase C-βαGqIII
Activates Rho guanine-nucleotide exchange 
factors (GEFs)
αG12IV
Inhibit adenylyl cyclase
Activate K+ channel
Activates K+ channel, inactivate Ca2+ channel
Activates phospholipase C-β
Activates cyclic GMP phosphodiesterase in 
vertebrate photoreceptors
α
βγ
βγ
α and βγ
α
Gi
Go
Gt
(transducin)
II
Activate adenylyl cyclase, Ca2+ channels
Activate adenylyl cyclase in olfactory sensory 
neurons
α
α
Gs
Golf
I
FunctionsAction 
mediated
Some 
member
Family
Table 1: The four major families of G-protein (adapted from 
isoft.postech.ac.kr/.../content/intro.html) 
 
1.3 G-protein-coupled signalling 
G-protein-coupled receptors are expressed on the cell surface and transmit extracellular 
cell signals by acting as ligand-activated guanine nucleotide exchange factors (GEFs) for 
the hetertrimeric G proteins to intracellular second messenger systems.  
All GPCR`s share a common signalling mechanism in that they interact with G proteins 
(heterotrimeric GTPases) to regulate the synthesis of intracellular second messengers 
such as cyclic AMP, inositol phosphates, diacylglycerol and calcium ions (Harmar, 
2001). Additional signalling pathways acting through protein kinases dependent on 
stimulation of some of the GPCR`s can also be activated, which demonstrates an 
additional level of complexity in their signal mechanisms (Knall and Johnson, 1998). 
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Several authors have shown that posttranslational modifications at GPCR`s including 
phosphorylation, glycolysation and enzymatic influence can play a role in the regulation 
of G-protein coupled signal transduction (Foord and Marshall, 1999; Pitcher et al., 1998). 
Importantly, the modulation of transmembrane signalling by G protein-coupled receptors 
constitutes the single most important set of therapeutic targets in medicine. Nearly 40% 
of all current therapeutics target GPCR`s (Brink et al., 2004). 
 
 
 
 
Figure 2: Diversity of the G protein-coupled receptor signalling transduction system 
(adapted from Gutkind) (Gutkind, 1998) 
C 
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? 
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G protein coupled receptor biological functions 
• Smell and taste 
• Perception of light 
• Neurotransmission 
• Function of endocrine and exocrine glands 
• Chemotaxis 
• Exocytosis 
• Control of blood pressure 
• Embryogenesis 
• Development 
• Cell growth differentiation 
• HIV infection 
• Oncogenesis 
 
 
1.4 Molecular biology and structure of VPAC Receptors 
There exist two classes of receptors for VIP; VPAC1R and VPAC2R which display 
different affinities and specificities (Fahrenkrug, 1993).  VPAC1R and VPAC2R are 
GPCRs with adenylate cyclase activity, which VIP shares with pituitary adenylate 
cyclase-activating polypeptide (PACAP), another neuropeptide (Severi et al., 2006). 
These receptors comprise one polypeptide chain with seven transmembrane segments, 
one N-terminal extracellular end and one C-terminal cytoplasmic end (Laburthe et al., 
1994). The VPAC receptors are distributed in a variety of organs and systems in the 
human body which suggests a potential global role in diverse biological processes. This 
thesis is focused on their potential role in cells of the immune system. 
The VAPC1 receptor was first isolated from a rat lung cDNA library by cross-
hybridization with a secretin receptor (Ishihara et al., 1992). The human VPAC1 cDNA 
was first isolated from HT29 human colonic adenocarcinoma cell line library (Goetzl et 
al., 1995b) and is located on short arm of human chromosome 3 (3p22) (Sreedharan et 
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al., 1995). The VPAC1R receptor consists of 457 amino acids with a long extracellular 
N-terminal and with a calculated Mw of 52 kDa. The gene is composed of 13 exons 
ranging in size from 42 to 1400 bp (Goetzl et al., 1995b). VPAC1 shows strong 
evolutionary conservation. 
Using reverse transcription-polymerase chain reaction (RT-PCR) analysis, it was 
previously demonstrated that VIP receptor 1 (VPACR1) is constitutively expressed in 
intraepithelial and lamina propria T lymphocytes from both small and large intestine. The 
VPAC1 receptor is also expressed in different areas of the human body including lung, 
kidney, intestinal tract and some areas in the brain (Ishihara et al., 1992). 
This receptor corresponds to the PACAP-II receptor and displays same affinity towards 
VIP and PACAP. 
VPAC2R was first cloned from a rat olfactory bulb cDNA library by Lutz and 
subsequently from a human placenta cDNA library (Lutz et al., 1993). VPAC2R was 
later characterized as a receptor for VIP and PACAP showing a similar response to both 
ligands. 
The human VPAC2 receptor gene is located on chromosome 7q36.3 (Mackay et al., 
1996). Lutz described the characterization of VPAC2 gene structure and promoter region. 
The VPAC2 receptor is encoded by 13 exons with intron sizes ranging from 68 bp (intron 
11) to 45 kb (intron 4) (Lutz et al., 1999). The VPAC2R receptor consists of 438 amino 
acids and with a calculated Mw of 49 kDa.
 
VPAC2R is expressed more selectively than VPAC1R. The VPAC2 receptor is expressed 
mainly in the CNS (thalamus & suprachiasmatic nucleus), but can also be detected in 
other tissues like the pancreatic B-islet cells, stomach, colon, lung, heart, kidney and 
immune system (Adamou et al., 1995; Cagampang et al., 1998; Ishihara et al., 1992; 
Usdin et al., 1994). Harmar examined the distribution of the VPAC2 receptor in mouse 
tissue (Harmar et al., 2004). VPAC2R was most abundantly found in the murine lung and 
gastrointestinal tract tissue. In contrast to VPAC1R,  VPACR2 was identified only in T 
cells from small intestine (Qian et al., 2001). VPAC2R is found at very low levels on 
resting monocytes and T cells, but its expression increases after activation of these cells 
(Lara-Marquez et al., 2001). 
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Two selective agonists for the VPAC1 receptor have been described: VIP (1-7) GRF (8-
27)-NH2 (VIP/GRF hybrid) and chicken secretin. The VPAC1 receptor antagonist Acetyl-
His1 [Dphe2,K15,R16,L27] is highly selective for VPAC1 receptor (Gourlet et al., 1997).  
There are two VPAC2 receptor agonists who are highly selective: Ro 25-1553 and Ro 25-
1392 (Gourlet et al., 1997; Xia et al., 1997). In addition a selective VAPC2 receptor 
antagonist myristoyl-[K12]VIP (1-26)KKGGT has been described (Moreno et al., 2000). 
 
Table 2: VPAC and PACAP receptors agonist and antagonist: 
 
 Gene name Human 
chromosome 
location 
Selective 
agonists 
Selective 
antagonist 
VPAC1 VIPR1 3p22 Chicken 
secretin 
VIP(1-
7)GRF(8-27)-
NH2 
VIP(3-
7)GRF(8-27)-
NH2 
VPAC2 VIPR2 7q36.3 Ro 25-1553 
Ro-25-1392 
myristoyl-
[K12]VIP (1-
26)KKGGT 
PAC1 ADCYAP1R1 7p14 Maxadilan PACAP(6-38) 
 
VPAC gene receptor expression has also been described in different human carcinomas. 
VPAC1 receptor expression was found in breast, lung stomach, liver, prostate, colon, and 
pancreas tumors (Gespach et al., 1988; Moody et al., 2000; Waschek et al., 1995). 
VPAC2 receptor expression has only been described in the benign leiomyoma (Reubi et 
al., 2000). Significant differences exist between VPAC1R and VPAC2R, both in 
structure and in function (Ganea, 1996; Nicole et al., 1998) and there are a number of 
reports suggesting opposing functions for these two receptors (Tsutsumi et al., 2002; Xia 
et al., 1996). 
These two receptors are highly conserved at the amino acid level suggesting that there 
may be common principles underlying the molecular mechanisms by which these 
receptors transduce agonist signals from the extracellular surface to the intracellular 
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second messenger systems (Segre and Goldring, 1993).  It is likely that these receptors 
have evolved from a common ancestral gene with strong selection pressure to maintain 
certain key molecular features which are necessary for this mechanism, but diverging in 
ligand specificity.  
In addition to VAPC1 and VPAC2, the receptor PAC1 has been shown to bind PACAP 
but not VIP. The VPAC2 and PAC1 receptors are 50% identical at the amino acid level, 
and have 60% identity within the transmembrane spanning domains (the receptor trunk). 
The PACAP receptors have traditionally been described as type 1 receptors that bind 
PACAP with greater affinity (100-1000X) than VIP, and the type II receptors that bind 
PACAP and VIP with equal affinity (Couvineau et al., 1994; Ishihara et al., 1992). 
 
 
 
 
 
 
 
 20 
 Table 3: VPAC receptor subtypes and their affinities (adapted from Rawling) 
(Rawlings and Hezareh, 1996) 
 
All these receptors belong to the secretin (Group II) G protein-coupled receptor family, 
which do not contain the consensus amino acid motifs defined for the rhodopsin/ß-
adrenergic (Group I) G protein-coupled receptor family (Segre and Goldring, 1993; Wess 
et al., 1997). Ligands for the secretin receptor family are all relatively large peptide 
hormones; all members stimulate adenylyl cyclase (AC), apparently through the 
heterotrimeric Gs protein; but many also couple to phospholipase C (PLC) stimulation 
through the Gq family (Hezareh et al., 1996; Offermanns and Simon, 1996). Activation 
of adenylyl cyclases result in production of cyclic AMP and activation of cAMP-
dependent processes. Further to their ubiquitous coupling to AC via the heterotrimeric G-
protein Gs, a number of the group II GPCR`s can activate additional signalling pathways. 
VPAC1R and VPAC2R are also able to couple to the IP3/[Ca2+]i pathway (Langer et al., 
2002). 
In the model of Langer, VIP induced [Ca2+]i increases were more efficient in the VPAC1 
receptor expressing CHO (Chinese hamster ovary) cells then in VPAC2 receptor 
expressing cells. VPAC1 receptor coupling can be attributed to both Gαq and Gαi. 
VPAC2 receptor coupling to Gα16 increases [Ca2+]i that allows the coupling of a wide 
VPAC1R 
 
VPAC2R 
 
PAC1R 
 
Name Relative affinity 
PACAP38~PACAP27~VIP 
 
PACAP38~PACAP27~VIP 
 
PACAP38~PACAP27>>VIP 
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variety of receptors to phospholipase C. Expression is restricted to hematopoetic and 
immune cells that express functional VPAC2 receptors (Langer et al., 2002). 
To better understand the physiology of these receptors, it is helpful to picture the 
downstream events that they elicit. The adenylate cyclase activity of VPACR`s is 
probably the most significant downstream aspect of these receptors in T cells. Indeed, in 
all systems analyzed the VPACR`s are associated with the Gs subunit and cause an 
increase in the cAMPi upon ligand stimulation. 
The physiologic downstream effects of increased cAMPi have been investigated in detail. 
These effects are mainly mediated by activation of the PKA (Protein kinase A) and the 
subsequent phosphorylation of CREB (cAMP response element binding protein). In the 
nervous system and in the immune system, the cAMP pathway is involved in inhibition 
of proliferation, as well as inhibition of apoptosis. 
Here it is important to provide some background that may illustrate the significance of 
cAMP pathway in T cells. A plethora of observations indicate a down regulation of 
intracellular cAMP upon T cell activation by co-stimulation with antiCD3/CD28. T cell 
activation is at the same time associated with increased IL-2 production and increased 
propensity to undergo apoptosis (personal communication with Dr.med. K. Bastani). 
Upon T cell activation, a T cell specific phosphodiesterase, the PDE7, is upregulated 
which causes the degradation of intracellular cAMP. On the other hand, increased cAMPi 
is associated with upregulation of the antiapoptotic protein bcl-2. Memory T cells with a 
CD45RO phenotype reverts to CD45RA phenotype when they are artificially treated with 
cAMPi increasing drugs. T cells bearing naïve markers as CD45RA or CD62L have 
increased amounts of cAMPi. These cells with a naïve phenotype are also more resistant 
to apoptosis (personal communication with Dr.med. K. Bastani). 
VPAC2R activates both adenylyl cyclase and phospholipase C. The VPAC2R was 
reported to be rapidly phosphorylated, desensitized and internalized after agonist 
exposure (McDonald et al., 1998). 
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Figure 3: VPAC receptors pathways 
Main second messenger pathways of VPAC receptors, which are both primarily coupled to the adenylate 
cyclase (AC)- stimulate Gs. Both ligands VIP and PACAP can activate the VPAC1R and VPAC2R with 
similar binding potency.  Abbreviations: GTP, guanosine triphosphate; GDP, guanosine diphosphate; ATP 
adenosine triphospate; CaM, calmodulin, PIP2, phosphatidyl inositol 4,5-bisphosphate; Ins (1,4,5) P3, 
inositol 1,4,5-trisphosphate; ER, endoplasmic reticulum; DAG, diacyl glycerol; PKC, protein kinase C. 
(Figure adapted from Dickinson (Dickinson et al., 1999)) 
 
Studies with mice deficient for VPAC2 suggest a role in circadian physiology, glucose 
metabolism, as well as Th differentiation of the murine immune system (Shen et al., 
2000).  The VPAC2 deficient mice showed increased Th1 cytokine profiles whereas mice 
expressing a human VPAC2 transgene within the CD4+ compartment showed a Th2 
dominance suggesting an inversion of the phenotype observed in the VPAC2 deficient 
mice (Goetzl et al., 2001; Voice et al., 2001). The immune and signalling events 
responsible for the phenotype observed in the KO and transgenic mice have not be 
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clarified.  The wide distribution of VPAC receptors suggests that VIP has many target 
sites and functions. 
 
1.5 Vasoactive Intestinal Peptide (VIP) 
VIP was first isolated by Said & Mutt 1970 from the porcine intestinal duodenum.  The 
amino acid sequence of porcine, canine, dog and rat is identical with the human VIP 
(Bunnett et al., 1984; Dimaline et al., 1984; Mutt and Said, 1974). VIP is a 28 amino acid 
neuropeptide and member of the secretin/glucagon hormone family and is described as a 
potent vasodilator (Barbezat and Grossman, 1971; Said and Mutt, 1970). VIP is found in 
various tissues, such as lung, liver, brain, thymus, spleen, and intestinal T lymphocyte 
subtypes (Gozes and Brenneman, 1989). VIP has a number of actions in the periphery, 
including vasodilatation, stimulation of electrolyte secretion, smooth muscle relaxation 
and homeostasis of the immune system (Gomariz et al., 2001; Gozes and Brenneman, 
1989). VIP is especially abundant throughout the entire enteric nervous system.  
 
1.5.1 Biochemical structure of vasoactive intestinal peptide 
The amino acid sequence of the porcine vasoactive intestinal octacosapeptide: His-Ser-
Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-
Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 (Mutt and Said, 1974). The VIP gene is located on 
chromosome 6 (6q24) of the human genome and consists of 9000 base pairs. There are 
seven exons and each exon codes for a specific functional domain (Gozes and 
Brenneman, 1989). VIP can act as a neuromodulator, neurotransmitter and secretagogue. 
The VIP precursor polypeptide (prepro-VIP) contains sequences encoding additional 
biologically active peptides, including peptide histidine isoleucine (PHI-27), peptide 
histidine methionine (PHM) and peptide histidine valine (PHV), which generate a single 
preproVIP molecule of 170 amino acids (Tatemoto and Mutt, 1981). VIP protein is 
posttranslational processed by proteases yielding the four peptides, of which three have 
known biological activity. After VIP is released from nerve cells it binds to the specific 
VPAC-receptors located on the surface of target cells. Ligand binding is specific, 
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saturable, reversible and temperature dependent. Much has been published about the 
subsequent signal transduction and second messenger system involvement. In a 
simplified form, ligand-receptor interaction activates a GPCR, which in turn activates 
adenelylcyclase which increases intracellular cAMP or alternatively, it activates 
guanylcyclase and increases cGMP. Both cAMP and cGMP are well known second 
messengers. 
VIP is rapidly metabolized in the human body, with a half life of only about one minute 
(Domschke et al., 1978). Misbin et al. have investigated the uptake and degradation of 
VIP by rat livers. The metabolism in the liver and internalization of   receptor bound to 
the VIP peptide with degradation from lysosoms is responsible for its fast metabolism 
(Luis et al., 1986; Misbin et al., 1982). Because of the high first pass effect of the liver, 
the plasma concentration of VIP is very low (<20pmol/l) and plays only a minor 
physiological role.  
VIP was originally thought to be only a gastrointestinal hormone. Later Fahrenkrug 
showed that VIP is also present in the brain and peripheral nervous system thus 
expanding the role of VIP as a neuropeptide with neurotransmitter and neuromodulator 
activity started (Fahrenkrug, 1993). 
VIP has well documented effects as a potent vasodilator and stimulator of electrolyte 
secretion (Barbezat and Grossman, 1971) and smooth muscle relaxation (Piper et al., 
1970). In the central nervous system, it is involved in regulating cerebral blood flow and 
circadian rhythms. VIP is a secretagogue for melatonin synthesis and release from pineal 
gland, insulin release from pancreas, and catecholamine release from adrenal medulla. 
VIP has a protective role in limiting oxidative damage in various tissues. VIP also 
stimulates glycogenolysis in the cerebral cortex and regulates cell death and 
differentiation of the retinal ganglion cells and sympathetic neuroblasts, and the signal 
induced by acetylcholine seems to be modulated by VIP (Kaiser and Lipton, 1990; 
Kawatani et al., 1985; Lundberg et al., 1982; Magistretti et al., 1981; Pincus et al., 
1990a). 
VIP and their receptors have been identified during early neural development and have 
been implicated in precursor cell mitosis, neurogenesis, and neuronal survival (Gressens 
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et al., 1993; Waschek, 1996). Moreover, in the immune system, VIP inhibits the 
proliferation of thymocytes and peripheral T cells (Sun and Ganea, 1993; Xin et al., 
1994). In T cells VIP and VPAC1R genes are expressed in double (CD4+CD8+) and 
single-positive (CD4+CD8-, CD4-CD8+) thymocyte populations, whereas double-
negative thymocytes lack expression (Delgado et al., 1996c). Delgado et al showed that 
VIP protects (CD4+CD8+) thymocytes from dexamethasone induced apoptosis through 
the VPAC1 receptor (Delgado et al., 1996a). 
The neuropeptide PACP was first discovered in 1989 as a hypothalamic hormone that can 
cause an increase of cAMP in rat anterior pituitary cells (Miyata et al., 1989). PACAP is 
present in two C-terminal amidated forms, PACAP27 and PACAP38 (27 and 38 amino 
acids, respectively), it shows a 68% sequence homology with vasoactive intestinal 
peptide (VIP) in the N-terminal 28 residues (Miyata et al., 1990). A single gene encodes 
the two known PACAP forms. 
 
VIP          HSD  AV FTD N Y TRL  RKQMAVKKYL NSI LN  
 
PACAP -38 HSD  GI  FTD S Y SRY RKQMAVKKYL AAV LGKRYKQRVKNK 
 
PACAP -27 HSD  GI  FTD S Y SRY RKQMAVKKYL AAV L 
 
Figure 4: Human sequence comparison of PACAP and VIP  
The sequence of PACAP-38, PACAP-27 and VIP with highlighted similarities. The functional similarity 
between VIP and PACAP-38 can be seen in the sequence accordance of the two peptides. 
 
Proteolytic processing of a PACAP precursor protein results in the two forms of PACAP 
(Arimura, 1992). PACAP-containing nerve fibers are present throughout the central and 
peripheral nervous system. The two molecular forms of PACAP exhibit a broad 
distribution and range of tissue concentrations. Dramatic changes in the levels of VIP, 
PACAP, and their receptors in the spinal cord after peripheral nerve injury suggest an 
important role in neuropathic pain states (MacKenzie et al., 2001). 
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The biological effects of PACAP are mediated through at least two types of high affinity 
receptors: the Type I PACAP-preferring receptor and the Type II receptor that does not 
distinguish between PACAP and VIP, and is referred to as the VPAC receptor. Molecular 
cloning of receptors with the pharmacological properties of each of these receptors has 
revealed that they are members of the G protein-couples receptor superfamily. The 
recombinant VPAC receptors bind VIP and PACAP with similar affinity and activate 
adenylyl cyclase. VIP is at least 1000-fold less potent in activating adenylyl cyclase and 
not active at all in phospholipase C stimulation (Spengler et al., 1993). The recombinant 
PACAP receptor binds PACAP with an affinity 1000 times higher than that for VIP. VIP 
binds with high-affinity to VPAC1 and VPAC2 receptors and with low-affinity to PAC1 
receptor. 
 
1.6 VIP and intracellular signalling 
VIP and PACAP can elicit many different cellular signalling events. This diverse range 
of indirect or downstream signals includes; activation of adenylyl cyclase, Ca 2+-
dependent processes and protein kinase C activation, nitric oxide synthase/protein kinase 
G, activation or inhibition of phospholipase A2, activation of tyrosine kinases, activation 
of extracellular-signal-regulated kinase mitogen-activated protein kinase, inhibition of 
JNK (c-Jun N-terminal kinase) and JAK (Janus kinase) and activation of 
phosphodylinositol 3-kinase (McCulloch et al., 2002). All VPACR characterized to date 
stimulate cAMP production and VIP stimulates cAMP in cells with VPAC receptors. 
It has also been suggested that several signalling pathways require internalization or 
sequestration of cell surface receptors by the clathrin-coated pit pathway (MacKenzie et 
al., 2001). Little is known about endocytosis of GPCRs, but McCulloch found that the 
VPAC2 receptor expressed in COS7 cells clearly shows greater internalization in cells 
cotransfected with wild-type arrestin-2. This suggests that for VPAC2 and possibly other 
group II GPCRs, access to arrestin-and clathrin-dependent routes of internalization may 
be possible, given the right cellular environment (McCulloch et al., 2002). Both secretin 
and VPAC2 receptors are probably phosphorylated by GPCR kinases (GRK) and by 
protein kinase A (McDonald et al., 1998; Shetzline et al., 1998). 
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Effector  Coupling mechanism Receptors 
AC Gs All 
PLC Gα11 PACi-null>PACi-
hopI>VPAC2/1 
 Gβγ from Gi/o VPAC2 
PLD ARF VPAC1/2=PACi-
hopI>PACi-null 
 Downstream of PLC PACi-null>PACi-hopI 
 
Table 4: Multiple signalling pathways from VPAC/PAC1 family receptors after Mc 
Culloch (McCulloch et al., 2002) 
Abbreviations: AC, adenylyl cyclase, PLC, phospholipase C, PLD, phosholipase D, PAC, pituitary 
adenylate cyclase, VIP, vasoactive intestinal peptide. 
 
PACAP and VIP peptides also protect adult neurons from apoptosis. PACAP 
significantly reduces neuronal apoptosis and cortical infarct size after ischemia (Ohtaki et 
al., 2006; Uchida et al., 1996). PACAP is frequently several orders of magnitude more 
potent than VIP in inducing trophic responses, suggesting that the peptide proliferation 
effects are mediated by PACAP-selective PAC1 receptors (DiCicco-Bloom et al., 2000). 
 
1.7 VIP and rheumatoid arthritis 
Rheumatoid arthritis (RA) is a debilitating chronic autoimmune disease of unknown 
etiology. It is characterized by inflammation in the joint and subsequent destruction of the 
cartilage and bone with joint deformities. Therapy of RA has been revolutionalize over 
the past few years as new drugs have became available for treatment, but for patients who 
continue to exhibit signs of inflammation and symptoms, few therapy options remain. 
The treatment of the disease as discussed in the American College of Rheumatology 
guidelines is focused on disease modifying medications including methotrexate, 
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hydroxychloroquin, sulfasalazine and anti-TNF-α-therapy. New treatment strategies 
concentrate on the use of vasoactive intestinal peptide (VIP).  
Studies have shown that in the onset and acute phase of rheumatoid arthritis, a Th1 
cytokine response predominates, whereas a Th2 response is associated with remission of 
the disease. Suppression of Th1 cells and enhancement of Th2 response has been one of 
the therapeutic approaches proposed for the treatment of RA. 
 
Figure 5: Overview of schematic representation of events occurring in rheumatoid 
arthritis (from Nature Reviews Drug Discovery, Smolen J 2003). 
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A growing body of experimental evidence suggests that VIP may exert regulatory effects 
on lymphocytes, which are generally anti-inflammatory in nature. It has been reported 
that VIP may inhibit lymphocyte adhesion and trafficking, suppress lymphocyte 
proliferation and generally decrease the natural killer activity of human and murine 
lymphocytes (Boudard and Bastide, 1991; de la Fuente et al., 1994; Moore et al., 1988; 
Rola-Pleszczynski et al., 1985). 
VIP biology could thus represent a new strategy for therapy of rheumatoid arthritis based 
on its effect on T-cell response. VIP has a suppressive effect on Th1 responses 
(demonstrated by decreased IFN-γ expression) as shown by several authors (Delgado et 
al., 1999; Goetzl et al., 2001; Voice et al., 2001). Macrophages and dendritic cells treated 
with VIP in vitro induce Th2-type cytokine release (IL-4 and IL-5) and inhibited Th-1 
cytokine release (IFN-γ and IL-2) in CD4 T cells (Delgado et al., 1999). VIP receptor 
deficient mice show an increased Th-1 type response as delayed-type hypersensitivity, 
whereas mice overexpressing VIP receptor show eosinophilia with high IgE and IgG1 
level and a typical cutaneous anaphylaxis as typical Th-2 response (Goetzl et al., 2001; 
Voice et al., 2001). 
In an animal model, treatment with VIP was found to significantly reduce the incidence 
and severity of collagen-induced arthritis, abrogating joint swelling and destruction of 
cartilage and bone. RA-like symptoms were induced by immunization of mice with type 
II collagen. After two immunizations VIP was administered in different doses and 
different injection time points for a period of two weeks. They could also show VIP 
blocks disease in mice that had already shown symptoms (Delgado et al., 2001). 
 
Vasoactive Intestinal Peptide in Immunity 
1. Prominent quantitatively in thymus, spleen, and body surface associated lymphoid               
     tissues  
2. Evokes T cell and macrophage trans-tissue migration. 
3. Regulates T cell and macrophage generation of cytokines. 
4. Alters T cell-dependent production of immunoglobulins. 
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5. Biases immune response toward immediate hypersensitivity and inflammation. 
6. Involvement in T cell apoptosis. 
 
1.8 Hypothesis 
mRNA splicing events lead to a number of variant forms of the PAC1 receptor with 
subtly different properties. At least five splice variants of the closely related rat PACAP 
receptor differing only in their predicted third intracellular domains, a region implicated 
in coupling of a variety of receptors to G proteins, are known. The short splice variant 
form of the receptor was designated PACAPR with the longer splice variant forms 
designated as hip, hop, or hip-hop isoforms of the PACAPR (Spengler et al., 1993). Four 
of these splice variants exhibited the multifunction signalling characteristics of PACAP 
receptors found in various cells, activating both adenylyl cyclase and inositol-
phospholipid-specific phospholipase C, while one variant activated only adenylyl cyclase 
(Spengler et al., 1993). 
To our knowledge, there have been no previous reports of splice variants of the VPAC2 
receptor. We hypothesized that splice-variants of VPAC2 receptor may exist in murine 
tissues as an additional control mechanism to regulate its function. 
The purpose of the present study was to use a PCR-based search to identify alternatively 
spliced mouse VPAC2 receptor expressed in different mouse tissues, and to thus, better 
characterize the biology of the VPAC2 receptor. The splice variant subsequently 
identified was further investigated by comparing the functional properties of mouse 
VPAC1 and the variant VPAC2 deletion after stable expression in human Jurkat T cells. 
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Objectives of the study: 
• Understanding the molecular mechanism of the VPAC receptors. 
• Generation of VPAC1R and deletion variant VPAC2R stable transfectants in a 
human T cell line. 
• Determining whether or not VPACR expression is associated with an increased 
intracellular cyclic AMP and influence of the known ligands on cAMPi. 
• Better understanding the role of VPAC receptors in T cell migration. 
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2. MATERIALS  
2.1 Bacteria  
Stratagene # 200236: XL1-Blue Supercompetent cells recA1, endA1, gyrA96, thi-1, 
hsdR17, supE44, relA1, lac [F´ proAB lacIqZ∆M15Tn10(Tet’)] 
 
2.2 Vectors 
pBluescript II KS (+): phagemid vector 
f1 (-) ori, ColE1 ori, lacI (not functionel), lacZ (for blue-white-selection), multiple 
cloning sites with flanking regionsT3- und T7-Promotor, ampicillin resistant, size 3.0 kb. 
 
pIRESneo3 Vector purchased from BD Biosciences (Cat #: 6988-1)  
The vector was designed for the production of stable cell lines expressing proteins in 
mammalian cells. This vector contains the internal ribosome entry site (IRES) of the 
encephalomycarditis virus (ECMV). This combination permits both the gene of interest 
and the neomycin selection marker to be translated from a single mRNA. 
Other features: multiple cloning sites, ampicillin resistant plasmid size 5.3 kb 
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Figure 6: pIRES vector  
 
2.3 Cells 
The cells used in this study are acute human T cell leukemia Jurkat Clone E6-1 (reference 
American Type Culture Collection (ATCC) TIB-152 Log # AO3823). The cells were 
purchased from the University of California (UCSF) tissue culture facility. Endogenous 
levels of the receptors could not be detected by realtime PCR (data not shown). The 
Jurkat T cell line was transfected with the vector. The resultant cell lines were maintained 
in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% Penicillin-
Streptomycin, and 500 µg/ml G 418 sulfate (Geneticin). 
 
 
 
pIRESneo3 
5275 bp 
IRES site 
CMV enhancer 
neo 
Ava I (1939) 
Bam HI (978) 
Cla I (911) 
Eco RI (972) 
Sma I (1941) 
Xma I (1939) 
Nco I (611) 
Nco I (2532) 
Apa LI (1831) 
Apa LI (3774) 
Apa LI (5020) 
Pst I (1306) 
Pst I (1956) 
Pst I (2153) 
Hin dIII (890) 
Hin dIII (1203) 
Hin dIII (1578) 
Hin dIII (1926) 
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2.4 Mice 
Wild-type C57BL/6 mice were ordered from Jackson Laboratory and housed at the 
animal facility at UCSF.   
 
2.5 Oligonucleotides  
The DNA oligonucleotides and the fluorometric-based kinetic RT-PCR primer & probes 
were purchased from Integrated DNA Technologies. 
 
2.6 Enzymes 
Applied Biosystems: AmpliTaq Gold polymerase 
New England Biolabs: all restrictionenzymes (EcoRI, SpeI), T4 DNA-Polymerase 
Roche: DNAseI, RNAseI, Expand High fidelity PCR system 
Gibco BRL Life Technologies: RNAout  
Qiagen: reverse transcriptase 
Invitrogen: Taq DNA Polymerase recombinant 
 
2.7 Chemicals and reagents 
Applied Biosystems: PCR buffer, MgCl2, plates and caps for fluorometric-based kinetic 
based RT-PCR 
Bio Whittaker Molecular Applications: Seakam® GTG® agarose 
Bio 101 systems: LB-Medium, LB-Agar Medium 
Calbiochem: G 418 Sulfate, albumin bovine serum fraction V fatty acid-free. 
Gibco BRL Life Technologies: pyrogen-free water. 
Invitrogen: Agarose, TRIzol® reagent # 15596-018, 100 bp DNA ladder 
Peprotech Inc: recombinant human SDF-1 α  
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Perkin Elmer: radioactive isotope [125I]-VIP (2200Ci/mmol, 638µCi/µg). 
Promega: set of dATP, dCTP, dGTP, dTTP 
Roche: TaqExpand #1732641 
Sekam: GTG Agarose (ligase free for cloning) 
Sigma: mouse collagen Typ IV, VIP (V6130-250UG), Ethidiumbromid 
UCSF tissue culture facility: RPMI 1640 with HEPES 25mM, 1x PBS (without Ca2+ and 
Mg2+), fetal bovine serum heatinactivated,  
All chemicals and reagents were purchased from Sigma (St Louis, MO, USA), Gibco-
BRL (USA), Calbiochem (USA), Invitrogen (USA), Promega (Madison, WI, USA), 
Qiagen (Germany), Roche unless otherwise indicated 
R&D system cAMP kit (low ph) #KGE002 
Radioactiv labeled I125-VIP 
 
2.8 Antibodies 
BD Biosciences: purified rat anti-mouse CD16/CD32 (Fcγ III/II Receptor, mouse Fc 
Block™) monoclonal Ab, purified hamster anti-mouse CD28 monoclonal Ab, purified 
anti-mouse CD3 ε chain (145-2C11), FITC labeled anti-mouse CD4 (L3T4) (RM4-4), 
FITC labeled mouse IgG2b κ isotype control, PE labeled anti-mouse CD25 (IL-2 
Receptor α chain, p55), PE labeled mouse IgG1 κ isotype control 
 
2.9 Solutions, media and buffer 
LB Medium 
Bactrotrypton  10g 
Yeast extract  10g 
NaCl   5g 
H2O dl  1l 
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LB plates 
LB-medium with 1,2% Bactoagar 
 
10X PBS  
NaCL   80g 
Na2HPO4  11.5g 
KCL   2g 
KH2PO4  2g 
H2O dl  1l 
 
TBE-Buffer (Tris-borate/EDTA) 
Tris-base    54.0g 
Boric acid     27.5g 
0.5 M EDTA (ph 8.0)   20 ml 
H2O dl    5l 
 
Cell culture growth medium for Jurkat cells 
RPMI 1640 
FBS heat inactivated  10% 
Penicillin   200 U/ml 
Streptomycin  200 U/ml 
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Cell cuture 
The Jurkat cells were cultivated in RPMI 1640 medium. Cells were incubated in the 
following conditions: 37 °C, 5% CO2, 96% humidity, medium was changed every third 
day. 
 
DEPC treatment of water solutions: 
To 1l of water solution 1 ml of diethylpyrocarbonat (DEPC) was added and the solution 
was incubated overnight at 37°C. Subsequent DEPC was inactivated through autoclaving. 
 
Other materials 
For all experiments we used water filtered through Millipore (Milli-Q). For all enzymatic 
reactions it was autoclaved before use. Neubauer hemacytometer was used for cell 
counting from Fisher Scientific, Pittsburgh, PA. 
 
2.10 Instruments 
Applied Biosystem: 7700 sequence detector thermocycler 
Beckman instruments: centrifuge  
Bio-Rad laboratories:  
Dynex Technologies: ELISA reader MRX revelation 
FACScan Becton Dickinson, Mountain View, CA 
TOMY MTX-150: table centrifuge 
Stratagene: Robocycler 40 temperature cycler 
 
 
 38 
2.11 Software 
CELL Quest (Beckton Dickinson, Mountain View, CA, USA) 
Easybound (non-linear regression tool from P.Heuler & G. von Euler, download online 
available) 
Excel 5.0 (Microsoft, USA) 
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3. METHODS 
3.1 RNA Isolation from mouse tissue 
Different tissues cell suspensions from a 6-wk-old C57BL/6 mouse (lung, spleen and 
thymus) were centrifuged, washed with 1x PBS, and lysed with 1ml of TRIzol 
(Invitrogen) (50-100mg tissue) and RNA was isolated according to the manufacturer´s 
protocol. Briefly the protocol contains following steps: tissue homogenization, phase 
separation, RNA precipitation, RNA wash with 75% ethanol and redissolving RNA in 
water (RNAse free). 
 
3.2 DNAse I digestion of RNA 
DNase I treatment eliminates DNA from the purified total RNA, to prevent amplification 
of genomic DNA targets in PCR. The final volume of reaction mix was 15 µl. The  
following reaction mix was incubated at room temperature for 15 min: RNA 10 µl, 
DNAse 2 µl (1U/µl), DNAse buffer 1.5 µl and water. To inactivate DNAse 1 µl of 25 
mM EDTA solution was added to the reaction mix and heat for 10 minutes at 65°C. 
 
3.3 First strand cDNA Synthesis for PCR 
DNAse-treated RNA was used for the synthesis of single-strand DNA with the Qiagen 
Omniscript RT kit. The kit contains reverse transcriptase, 10x transcriptase buffer, 
dNTPmix and H2O. Rnase inhibitor (10 units/µl) and Oligo-dt primer (10µM) was added 
purchased from invitrogen. Afterwards 10 µg total RNA was absorbed in 12 µl water.  
To this RNA preparation the following master mix was added; 2 µl (10µM) Oligo-dt 
primer, 1 µl Rnase inhibitor (10 units/µl), 2 µl 10X transcriptase buffer, 2 µl dNTP 
(5mM/each), 1 µl reverse transcriptase enzyme. The final reaction volume 20 µl was 
incubated for 1 hour at 37°C. Afterwards the preparation was stored at -20ºC or 1 µl 
cDNA was used for one PCR reaction. 
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3.4 Cleaning methods for nucleic acid 
3.4.1 Phenol extraction: To exclude proteins of the DNA preparation (minimum 100 µl) 
we added the same volume of TE saturated Phenol and vortexed for 1 min. Afterwards 
the mixture was centrifuged 3 min at 13000 rpm. The aqueous solution on top was 
transferred in a new tube and the same volume chloroform/isoamylalcohol (24:1) was 
added vortexed for 1 min and centrifuged 3 min at 13000 rpm. The aqueous solution 
contains the DNA preparation free of protein.  
 
3.4.2 Ethanol precipitation: The DNA preparation was mixed with 1/10 volume 3M 
natriumacetat (ph 4.8), subsequently 2.5 volume -20°C absolute ethanol was added. The 
mixture was gently mixed and for at least 1 hour at -20°C or for 20 minutes at -80°C 
stored. The DNA pellet was afterwards centrifuged for 30 minutes at 13000 rpm at 4°C. 
The precipitation was washed with 0.5 ml -20°C absolute ethanol and then air dried for a 
couple of minutes before resolved in suitable volume of water (DEPC-treated). The 
nucleic acid concentration of the sample is determined with a photometer. 
 
3.5 Amplification of DNA with PCR  
Polymerase chain reaction (PCR) (after Saiki 1985) was used to amplify single or double 
target DNA fragments selective in vitro. The purpose of PCR is to make increased 
numbers of copies of a gene. The double-strand genomic DNA is melted with heat into 
two single strands, which can bind specific to oligonucleotide primer (20 nt long) that 
flank the DNA fragment of interest to start the polymerase reaction. The DNA-
polymerase adds complementary nucleotides to the 3’OH end of the primer to generate a 
new double-strand. In the next step the double-strand DNA is separated to a single –
strand DNA through heat and the reaction can start again. The cycles are repeated 
orbitrary, so during the first 30 cycles there is an exponential amplification of the 
examined DNA fragment. One important condition for the success of the reaction is that 
the primers bind specifically. The primer sequence must be known for specific synthesis. 
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The PCR is performed using a thermocycler which was programmed with temperature, 
time and cycle frequency. 
Overview of the PCR steps: 
1. Denaturation of matrix DNA: 94°C 
2. Annealing of primer: between 58-62°C around 1 min 
3. DNA synthesis: 72°C depending on the amplification length, for 500 bp around 
30 s, most of the times 35 cycles were used. 
 
 For PCR thermostabil Polymerases “Expand High fidelity PCR system (Roche), Ampli 
Taq Gold Polymerase (Applied Biosystems), Taq DNA Polymerase recombinant 
(invitrogen), thin-wall tubes and the thermo block Robocycler 40 (Stratagene) were used. 
A PCR reaction mix of 25 µl consisting of the following reagents: 1X buffer, dNTP (0.2 
mM), Taq polymerase (1 µl/100 µl), Mg (1.5 mM), H2O +primer (25 pmol 3’and 5’) + 
cDNA (1 µl) was used. Following PCR amplification, the PCR products were analyzed 
with electrophoresis. Electrophoreses PCR product aliquots were transferred (10 µl) on a 
1.5% agarose gel (stained with ethidiumbromide) and lanes with DNA molecular weight 
marker were included. The 6X probe buffer (with bromphenolblue dye) at a volume 1/10 
was added to the DNA product before transfer. The 1.5% agarosegel was generated as 
following: 22.5g agarose was mixed with 150 ml 1X TBE and heated up in the 
microwave for 1 min until the solution was clear. Than the gel solution cooled down and 
0.5 µg/ml ethidiumbromide was added. The solution was poured warm in the gel 
chamber and was than loaded. (Loading buffer was 1X TBE) 
The electrophoresis was performed at 100 V for a gel size of 12x14 cm² (150 ml gel). 
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Primer name Primer sequence Product 
size 
Annealing 
temperature 
T7  sequencing 
pBluescript 
KS(-) 
R: 5’-GAA TTG TAA TAC GAC TCA CTA TAG-3’   
T3 sequencing 5’-CTC GAA ATT AAC CCT CAC TAA A-3’   
mHPRT F:5’-CTG GTG AAA AGG ACC TCT CG-3’ 
R:5’-TGA AGT ACT  CAT TAT AGT CAA GGG CA-
3’ 
108 bp 55°C 
HPRT-SpeI 
 
HPRT-EcoRI 
F:5’-GAC TAG TCC GCC ATG GCG ACC CGC 
AGT CCC AG-3’ 
R:5’-GGA ATT CTT AGG CTT TGT ATT TGG CTT 
TTC CAG TTT CAC-3’ 
 
657 bp 65°C 
mVPAC2 F:5’-AGA TGT TGG TGG CAA TGA CCA G-3’ 
R: 5’-GTA GTG GAC GCC AAA CAG GG-3’ 
F: 5’-ACT TTT GCG TTG ATG AAG TCT CTG CTT 
TCT GTT-3’ 
R: 5’- TGT ATT TCT AGA TGA AAG CGA CAT 
TCT GGA TGG-3’ 
78 bp  
63°C 
mVPAC2 E11 
sequencing 
R: 5’-GTGGACGCCAAACAGGG-3’   
mVPAC1 E11 
sequencing 
R: 5’-GGGAAGAAGGCAAACATGACATAG-3’   
pIRES F: 5’-CTC ACT ATA GGG AGA CCC AAG CTT-3’ 
R: 5’-CGC TTT TGA GAG GGA GTA CTC AC-3’ 
 
 
58°C 
mVPAC1 F:5’-CCG AAT CCT GGT TCA GAA GCT-3’ 
R:5’-GGG AAG AAG GCA AAC ATG ACA TAG-3’ 
134 bp  
59°C 
mVPAC2-EcoRI 
test Jurkat 
R: 5’-GGA ATT CCT AAA TGA CTG AAG TCT 
CTG ACT GCA GGA-3’ 
1314 bp 65°C 
mVPAC2-SpeI F:5’-GAC TAG TCC ACC ATG AGG GCG TCG 
GTG GTG CTG A-3’ 
 65°C 
mVPAC2ex10F  
mVPAC2ex11R 
Intron splicing  
F:5’-GAGTTATGTGTTGGTTCCTTCCA-3’ 
R: 5’-GCCATCTTCTTTTCAGTTCACAC-3’ 
 
 59°C 
mVPAC1- 
EcoRI test 
Jurkat 
R: 5’-GGA ATT CTC AGA CCA GGG AGA CCT 
CCG CTT-3’ 
1380 bp 65°C 
mVPAC1-SpeI F: 5’-GAC TAG TCC ACC ATG CGC CCT CCG 
AGC CTA CC-3’ 
 65°C  
Table 5: Primer sequences used  
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3.6 Cloning of the mVPAC1 and mVPAC2 receptor  
In order to obtain the full-length mVPAC1 and mVPAC2 cDNA, RNA was isolated from 
thymus, spleen and lung tissues of normal 6–8-week-old C57BL/6 male mice. After 
sacrificing the animal by cervical dislocation, the tissue was immediately put in TRIzol 
and RNA (expected 30-100 µg RNA) was isolated according to the manufacturers’ 
protocol. RNA was DNase-treated for 30 minutes at 37°C. The synthesis of first-strand 
cDNAs was performed using the Superscript II system (Invitrogen). VPAC2 DNAs in the 
first-strand cDNA array were amplified by PCR with platinum TaqDNA polymerase 
(Invitrogen) and primers for sequences at the ends of the coding region: 5'-gac tag tcc acc 
atg agg gcg tcg gtg gtg ctg a-3' (forward (SpeI)) and 5'-gga att cct aaa tga ctg aag tct ctg 
act gca gga a-3' (reverse (EcoRI)) VPAC1 primers 5'- gac tag tcc acc atg agg gcg tcg gtg 
gtg ctg a -3' (forward (SpeI)) and 5'-gggaagaaggcaaacatgacatag -3' (reverse (EcoRI)). 
Mouse VPAC1 and VPAC2 containing the open reading frame was amplified using High 
Fidelity Taq DNA polymerase (Roche) with following reaction conditions: 95°C 2 min 
for one cycle, 95°C 45 s, 60°C 1 min, 72°C 2 min for 3 cycles, 95°C 45 s, 65°C 1 min, 
72°C 5 min for 30 cycles.  
PCR products were separated on a 1% clean agarose gel and visualized by ethidium 
bromide fluorescence. The expected size of the mVPAC1 PCR product was 1380 bp, for 
mVPAC2 1314 bp and for mHPRT 657 bp (see picture next page). The PCR products 
were digested with the restriction enzymes SpeI and EcoRI.  
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Picture 1: Cloning PCR from mouse lung tissue mHPRT 656 bp (left), mVPAC1 1380 
bp (middle) and mVPAC2 1314 bp (right) (all three in double bands; primer 
EcoRI/SpeI, ladder from 250 to 2000bp). 
 
Individual VPAC2 DNAs were isolated by 1% agarose gel electrophoresis and introduced 
into pBluescript II SK(+) phagemids (Stratagene, La Jolla, CA) at the SpeI/EcoRI sites 
for transformation into XL2-Blue MRF’ Ultracompetent cells. Selection of colonies with 
PCR-detectable VPAC2 inserts in plasmid mini-preparations (Qiagen, Valencia, CA), and 
determination of the sequences of these VPAC2 DNAs with primers for vector 
sequences: 5'-ctcgaaattaaccctcactaaa-3' (forward) and 5'-gtggacgccaaacaggg -3' (reverse) 
(ELIM Biopharmaceuticals, Inc., Hayward, CA) was performed. Multiple DNAs 
encoding wild-type and deletion-variant VPAC2 receptors were subcloned into the 
pIRESneo3 bicistronic expression vector (BD Biosciences) at the NheI/EcoRI sites and 
re-sequenced with the pIRES primers: 5'-ctcactatagggagacccaagctt-3' (forward) and 5'-
cgcttttgagagggagtactcac-3' (reverse).  
mmmmm mHPRT 656 bp mVPAC1 1380 bp 
ladde
r
 
 mVPAC2 1314 bp  
 
 
1500 bp  
 
 
1000 bp 
 
 
 
250 bp 
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Picture 2: PCR of Jurkat transfectants mVPAC1 1380 bp and mVPAC2 1314 bp, 
ladder from 250 to 2000 bp. 
 
3.6.1 Plates culture and solution cultures 
LB-medium was autoclaved with 15g/l agar-agar. After cooling down to 55°C the 
ampicillin 100µg/ml for antibiotic selection was added. The warm medium was filled into 
sterile petri dishes plates. The plates will be dried for 30 minutes at 37°C. The dried 
plates can be stored for weeks at 4°C. The bacteria were poured after transformation on 
the dried plates (37°C for 30 minutes) 500 ml LB-medium (Ampicillin added) were 
transfected with one single colony and shook overnight at 37°C with 280 Upm. 
 
3.6.2 Isolation of DNA fragments from agarose gels 
The specific DNA fragment (2 bands) were cut from the gel with a sharp scalpel and put 
into tubes, weighed gel (160-200 mg) and treated by following the instructions of the gel 
extraction kit (Qiagen). The plasmid DNA was isolated from the gel (3000 bp) after 
digestion with EcoRI and SpeI the gel extraction kit was used according to the protocol. 
The pBluescript phagemid vector was also cut with the same restriction enzymes.  
 
 
 
mVPAC1 mVPAC2 
ladde
r
 
 
 
 
 
<-1500 bp 
 
<-1000 bp 
 
 
<-250 bp 
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3.6.3 Ligation of the plasmid  
The fragment was subsequently cloned into the NheI (compatible ends with SpeI) and 
EcoRI sites of the eukaryotic expression vector pIRESneo. After transformation of E.Coli 
bacteria with the new constructs, single colonies were picked and the cloned sequences 
identified by DNA sequencing (performed by ELIM company). 
 
3.6.4 Transformation protocol  
The ultracompetent bacteria’s were thawed on ice and 5 µl of ligation mixture was added 
to 100 µl of bacteria which was gently swirled. The bacteria were incubated on ice for 15 
minutes, heat-pulse the tubes in a 42°C water bath 20 seconds, incubated on ice for 2 
minutes. Then 0.9 ml of preheated (42°C) NZY+ broth was added and the tubes were 
incubated at 37°C for 45 minute with shaking at 225-250 rpm. 50 µl or 5 µl of the 
bacteria were plated on LB-agar plates (ampicillin 100 µg/ml) and incubated overnight at 
37°C. 
 
3.6.5 Generation of stable human Jurkat T cells transfectants 
The introduction of a specific DNA segment into the Jurkat T cells was performed by 
transfection of the expression plasmid into the cells. The Jurkat T cell line is an 
immortalized human leukemic T cell line. Jurkat T cells are particularly robust producers 
of IL-2 after stimulation with phytohaemagglutinin (PHA) (Abraham and Weiss, 2004). 
 
3.6.6 Electroporation 
Electroporation was used for transfection. This method is suitable for cells in suspension 
such as the Jurkat T cells. The cells and DNA fragment were treated for milliseconds 
under an electric field, such that the DNA fragments penetrated into the cells.  The cells 
were first centrifuged 5 min at 300 x g and washed with 10 ml PBS resuspended and 
counted. After a second centrifugation, the cells were resuspended at a concentration of 
1.2 x 107 cells in 800 µl PBS.  
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Jurkat cell suspension was then mixed with 20 µg linearized DNA (mVPAC1, pIRES or 
mVPAC2 deletion/intron11) construct. The cell suspension was filled into a sterile 
electroporation cuvette with 4mm electrode distance, and was electroporated at 240 
Volt/500 µF.  The cell suspension was incubated for 10 minutes on ice and then 
transferred into a cell culture flask (2.5 x 106 cells) with regular growth medium. 
After 24 h, the Jurkat cells were washed and cultured for 2 days in complete RPMI 1640 
medium containing 10% fetal bovine plasma, 100 units/ml penicillin G, and 50 µg/ml 
streptomycin. Geneticin (Invitrogen) then was added to the cultures in steps of 200, 400, 
and 600 µg/ml every 4–6 days.  
 
3.7 Ligand competitive binding assay 
Binding assays can provide information about the affinity of sites as well as the total 
number of binding sites per cell. Binding assays involve a timed incubation with the 
radioligand and the cells expressing the receptor of interest at optimized temperature and 
conditions. Binding is allowed to proceed until it reaches equilibrium. Termination of the 
assay separates free from bound and the radioactivity remaining counted. The existence 
and characterization of specific VIP binding sites on immune cells and lymphocytic cell 
lines has been documented initially through binding studies (Delgado et al., 1996b). 
 
 
 
 
 
 
 
 
Table 6: VIP Receptor Binding Properties (after Moody T 1986) 
0,9 3,28 3,62 KD (nM) 
Krebs-Ringer 
 
Krebs-Ringer 
 
50 mM HEPES Buffer 
 
9000 per cell 0.3, 1.5 pmol/mg 
protein 
0.2, 8.4 pmol/mg 
protein 
Density 
37 25 37 
 
Temperature (°C) 
 
[125I] VIP [125I] VIP [125I] VIP Radiolabeled 
probe 
Pancreatic acini Brain 
slices 
Brain  
homogenate 
Parameter 
 48 
 
In order to estimate the binding of an agonist we determined 125-Iodine-VIP binding using 
live cell suspensions. The cold PBS washed cell suspension at 1Mio/well was 
resuspended in 25 µl binding media containing: RPMI 1640 with Hepes 25 mM, 1% 
BSA, 0.05% Azide and incubated with 25 µl of different concentrations of VIP 10-6 M to 
10-10 M. Then 25 µl radioactive 125I-VIP was added at a concentration of 10-9 M. The 
plate was incubated under constant shaking at room temperature for 1.5 hours. 
Subsequently the cell suspension (total 100 µl) was put on top of 800 µl cold 10% 
sucrose and centrifuged 3000 rpm at 4 ºC through this gradient for 10 minutes. Very 
slowly the top layer of about 800 µl was removed and the left cell suspension was 
transferred into counting tube. The result was determined by using a Packard Cobra 
Auto-gamma counter and Easybound software.  
 
3.8 cAMP ELISA assay 
For the quantitative determination of cyclic AMP (cAMP) concentrations in the cells we 
used an R&D systems USA cAMP (low pH) kit. Adenosine 3’,5’-cyclic monophosphate 
(cAMP) is ubiquitous second messenger involved in various cellular activities in many 
cell and tissue types. Receptor-mediated activation of the G protein activates adenylate 
cyclase (AC) by generating cAMP from ATP and subsequently activating protein kinase 
A (PKA). 
This assay is based on the competitive binding technique in which cAMP present in a 
sample competes with a fixed amount of horseradish peroxidase (HRP)-labeled cAMP 
for sites on a mouse monoclonal antibody. The monoclonal antibody becomes bound 
during the incubation time to the goat anti-mouse antibody coated on the microplate. The 
microplate is washed to remove excess conjugate and unbound sample. To determine the 
bound enzyme activity a substrate solution is added. Afterwards the color development is 
stopped and the absorbance is read at 450 nm by a plate reader. The intensity of the color 
is inversely proportional to the concentration of cAMP in the sample. 
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The cells were washed twice with RPMI put into a 96 well/plate and pretreated with 
phosphodiesteraseinhibitor 3-isobutyl-1-methylxanthine (IBMX 0.6mM) at 37ºC for 15 
minutes. VIP in different concentrations (10-6 M to 10-9 M) was added, and after an 
additional incubation time at 37ºC for 15 minutes, was followed three washes with 0.9% 
NaCl, the cells were lysed with the provided 0.1 N HCL solution. After adequate lysis 
had occurred, the samples were centrifuged at 600 xg and assayed immediately or stored 
at -20ºC.  
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Figure 7: Direct competitive ELISA to detect soluble antigens. Abbreviations: Ag: 
antigen; Ab: antibody; E: enzyme. 
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3.9 Transwell migration assay 
Cell migration is a fundamental function of normal cellular processes, including 
angiogenesis, embryonic development, wound healing, inflammation and immune 
response. Costar Transwell® cell culture chamber 6,5 mm with 5 µm pore size filter were 
coated on the lower side with mouse collagen type IV (10 µg/ml) over night at 4ºC, 
washed twice with PBS and air-dried. The lymphocyte cell suspension 2 Mio/200 µl was 
placed on top of the filter. In the lower chamber different concentrations of stimulus was 
added to make 500 µl. The plate was then incubated for 6 hours at 37°C. Afterwards the 
whole 500 µl in the bottom chamber was centrifuged, and resuspended in 100 µl trypan 
blue stain 0.4%. The dye exclusion test was used to determine the number of viable cells 
present in a cell suspension. It is based on the principle that live cells possess intact cell 
membranes that exclude certain dyes, such as trypan blue, whereas dead cells do not. In 
this test, a cell suspension was simply mixed with dye and then visually examined to 
determine whether cells take up or exclude dye. 10 µl of the total volume was used to 
count with a Neubauer hemacytometer. To count cells, 10 µl of the culture was applied to 
a clean, covered hemacytometer. Upon examination under a microscope, the cells in each 
corner square are counted and averaged. Using these numbers, the total number of cells 
per ml of culture was determined (cells/ml= counted cells / 4x dilution x 104). 
Statistical analysis was performed using an unpaired t-test. 
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Figure 8: Transwell® permeable Support. The porous bottom of the insert provides 
independent access to both sides to the cells. 
 
 
3.10 Flow cytometry apoptosis assay with 7-AAD 
Fluorescence-activated cell sorting (FACS) was performed to quantify the expression of 
7-Amino-actinomycin D (7-AAD) on the surface of the Jurkat T cells. Flow cytometry is 
a method to analyze the presence of antigens on cells by immunofluorescence. The cells 
will be labeled with a fluorescent antibody and then analyzed using a flow cytometer.  
Due to the fragility of cells undergoing programmed cell death, rapid methods that 
maintain cells as close as possible to their natural state were used to provide the most 
reliable results. The rapid 7-AAD staining method uses unfixed cells and thus permits the 
detection of changes in light scatter parameters and their correlation with other indicators 
of programmed cell death. However, one drawback of using any live staining method for 
measuring apoptosis is the variability of dye uptake in different cells and its possible 
change through certain treatment conditions. 
Principle of the assay 
Apoptotic cells, probably due to a change in membrane permeability, take up some 7-
AAD and become 7-AADdim compared to live cells which remain 7-AAD-bright. Late 
Transwell insert 
 
Upper compartment 
Lower compartment 1m
m 
     
Microporous membrane 
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apoptotic or necrotic cells which have lost membrane integrity appear 7-AADbright 
(Philpott et al., 1996; Schmid et al., 1994). 
Preparation of 7-AAD stock solution 
Dissolve 7-AAD powder (1mg) first in 50 µl of absolute methanol, and then add 950 µl 
of 1 X PBS. Final concentration is 1mg/ml. Keep solution at 4°C protected from light. 
Solution can be stored for at least up to 6 months. 
Jurkat transfectants were incubated at 1 x 106 cells/ml overnight in fresh RPMI medium 
containing 10% FBS. Triplicates of cultured cells were incubated on ice for 60 minutes in 
polystyrene tubes with 20 µl 7-AAD (7-amino-Actinomycin D) and subsequent analyzed 
in flow cytometry. Analysis was performed with CellQuest software program. 
3.11 Statistics 
Data was analyzed by the Student’s t test for independent samples. 
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4. Results 
4.1 Alternative splicing of VPAC2 receptor 
In our effort to isolate mVPAC2 splice variants, we used a series of different mouse 
tissues for our PCR based search. At the time of the studies, the full-length cDNA of 
VPAC2 had not been cloned from the mouse thymus, spleen or lung. Since high 
expression levels of VPAC1 and VPAC2 are known to be present in the lung, we used 
mouse lung mRNA as the source for cloning.  
A mouse VPAC2-specific primer designed within the 3’untranslated region was used in 
reverse transcription reactions (mVPAC2 RT primer) and VPAC2 specific cDNAs were 
synthesized using the RT primer and mRNAs isolated from the mouse thymus, spleen 
and the lung. Subsequently, using the aforementioned mVPAC2 cDNAs as templates, 
PCR`s were performed in order to amplify the full-length translated region of VPAC2.  
The ends of the PCR products were digested with the restriction enzymes SpeI and 
EcoRI, and subsequently cloned into the NheI (compatible ends with SpeI) and EcoRI 
sites of the eukaryotic expression vector pIRESneo. After transformation of E.coli 
bacteria with the new constructs, single colonies were picked and the cloned sequences 
identified by DNA sequencing. 
Several sequences in the thymus and spleen showed a 39 bp deletion of the exon11 at the 
junction to the exon 12. This cDNA species could be expressed as a 7-transmembrane 
receptor with a shortened last transmembrane domain (data not shown). 
In the lung, one alternatively spliced cDNA clone was found where the initial 21 bp of 
the exon 12 was deleted. This splice variant would not lead to premature stop codons and 
could potentially produce a correctly folded 7-transmembrane protein with a shortened 
last transmembrane domain. Deletion mutant: mVPAC2 A T3 was identified where C>T 
at 1239, and T>C at 1117, and the stretch 1076 to 1098 (21 bp) was found deleted. This 
region belongs to the exon 12, same area as the hip and hop in the PACAP splice variant 
is mutated. 
An additional clone was found to have an unspliced intron 11 (1095 insertion of intron 
11), but was otherwise intact. Intron 11 with only 65 bps is at the limit of biologically 
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permissive intronic sequences. This sequence was detected in several sequences in the 
mouse lung cDNA. The small length of this intronic sequence is conserved in human and 
mouse (68bp in human). This conservation between human and mouse suggests its 
potential importance for the function of VPAC2. 
Generally there are regulatory mechanisms present in cells that control splicing. The 
retention of this intron sequence in the processed mRNA would probably cause nuclear 
retention of the message, and even if this message could escape the nucleus, a premature 
stop codon in this message would rob the protein of its proposed signal transducing 
elements. All of the frequently detected splice variants showed alternative splicing of 
intron 11 at either the 5’ or 3’ end. Nevertheless, it was determined that the transfection 
of Jurkat cells with this cDNA (VPAC2-INRON11) could potentially give rise to the full 
length VPAC-2 protein (because introns are normally spliced, such that this sequence 
could be removed during expression). The full length VPAC-2 cDNA (which had one 
silent mutation in the coding region) was cloned on the assumption that splice-variants 
could modify the immunoregulatory contributions of the VIP-VPAC2 axis. The 
identification of splice variants in murine tissues suggested that they could give rise to 
expression of novel receptors with unique biological activity. To further investigate the 
biological relevance of these isoforms the cDNA products were subcloned into the Jurkat 
T cell line. The VPAC2-INRON11 (as introns are normally spliced), and the full length 
cDNA VPAC2 (with 21 bp deletion of exon 12) were selected for more intensive 
functional analysis.  
4.2 Stable mVPAC human Jurkat T cell transfectants 
Then we set out to generate T cell line that express mouse VPAC1R and VPAC2R. For 
this purpose we chose a human leukemic Jurkat T cell line that is CD4(+), and produces 
significant amounts of IL-2. One of the additional reasons for this selection was based on 
the publication from Qian et al, where VPACR2 was identified primarily in T cells (from 
small intestine). Further studies on purified subpopulations of T lymphocytes have 
indicated the existence of VPAC2R in CD8(+) T cells, but not CD4(+) and CD4CD8 
double negative T cells, although all these three subpopulations displayed VPAC1R 
(Qian, BF 2001).  
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The human Jurkat T cell line was transfected with a vector containing cDNA for the 
intron 11 (VPAC2-i11). A Kozak consensus sequences necessary for efficient ribosomal 
binding was built into the 5` end of the cDNAs as the endogenous sequence was lost in 
the subcloning. For this purpose the relevant primers were generated (Kozak, 1987). 
The cDNAs were then subcloned into a pIRES (internal ribosome entry site) vector that 
allows bicistronic expression of the desired clone. Stable Jurkat transfectants of mVPAC1 
and pIRES (as control) were generated. We were not surprised to find that the production 
of a stable transfectant cell line with the full length cDNA of VPAC2 was unsuccessful. 
Sequencing indicated that the inserted intron in this sequence is precisely spliced, but 
included an additional event that was not detect in the other clones: a stretch of 78 bp 
(amino acid 115-138, 26 amino acids) from the first extracellular domain into the parts of 
the first transmembrane domain (126-159) is deleted in these cells. The missing sequence 
is equivalent to almost the whole exon 5, except 3 nucleotides at the beginning that are 
AGT>AGA, which is S>R exchange at the beginning. Such a transcript would be 
transcribed, although a region of the extracellular and first transmembrane of the receptor 
is missing. This region may be important for ligand binding. None of the conserved 
cysteine residues are deleted. The amino terminus and second and third extracellular 
loops posses five cysteine residues that are highly conserved among VPAC1/2, PACAP, 
secretin and glugacon receptors that may form disulfide bonds necessary for agonist 
binding conformation as shown for rhodopsin (Karnik et al., 1988). We used this mouse 
VPAC2 transfectants (mVPAC2del_78 ) as working cell line. 
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Table 7: Structures of mVPAC2 GPCRs and level of mRNA expression in Jurkat T cell 
transfectants 
Protein prediction analysis (hydropathy analysis) results indicated that a protein 
generated from this altered transcript could be expressed as a seven transmembrane 
protein. At present the significance of these, possibly posttranscriptional modified 
mRNAs are not understood. However, AT rich sequences within the coding sequence as 
well as two ATTTA pentamers suggest that the VPAC2 sequence is an unstable mRNA 
and therefore subject to posttranscriptional modifications such as mRNA editing and 
mRNA splicing. 
The binding of this protein to VIP was then evaluated in more detail. The protein could in 
theory act in its function as an adenylate cyclase activator, with or without VIP, or 
potentially with another molecule as a ligand. In one case, we found a pattern of 
alternative splicing of VPAC2 that would delete the entire last cytoplasmic domain. If 
this protein was translated, it could in theory act as a decoy VIP receptor with no 
signalling function.  
VPAC2 has several AUUUA elements. These are found in the mouse as well as in the 
human system, within the untranslated 3’ region as well as within the coding region. 
Structures 
DNA sequences  
Wild-type  
 
 
Deletion mutant 78bp 
 
Amino acid sequences  
Wild-type  
 
Deletion mutant 78bp  
 
 
100FPDFIDACGYNDPEDESKISFYILVKAIYTLGYSVSLMSLTTGSIIICLFRRKLHCTRNYI160 
 
100FPDFIDACGYNDPEDER................................................................SIIICLFRRKLHCTRNYI160 
 
390cgaggatgag a gtaag atct cgttttatattttggtgaag gccatttata 
ccttgggcta cagtgtttct ctgatgtctc tt acaacagg aagcataatt 
atctgcctct500  
 
390cgaggatgag …………………………………………………………… aagcataatt 
atctgcctct500  
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AUUUA elements are known to destabilize the mRNA, so it was anticipated that making 
stable transfectants for VPAC-2 in Jurkats could prove difficult (Malter, 1989). 
A Jurkat mVPAC2del_78 ,  mVPAC1 stable transfectant and a pIRES control cell line were 
created. Using RT PCR and subsequent sequence analysis, endogenous hVPAC1 and 
hVPAC2 could not be detected in the Jurkat cells before transfection by real-time PCR 
(data not shown). Nevertheless, the subsequent binding and cAMP studies suggest a low 
level of endogenous hVPAC expression in Jurkat cells (see results below). 
 
4.3 VIP Competitive Binding Assay of Jurkat T cell transfectants 
Binding assays can provide information about the affinity of sites as well as the total 
number of binding sites per cell. Binding assays involve a timed incubation with the 
radioligand and the cells expressing the receptor of interest at optimized temperature and 
conditions. Binding is allowed to proceed until it reaches equilibrium. Termination of the 
assay separates free from bound and the radioactivity remaining is counted. 
Competitive binding studies using live cells and 125I-labeled VIP as a radioligand were 
performed with all three transfectant cell lines. We demonstrated that receptors with a Kd 
of approximately 1-2 nM were present on mVPAC2del_78 transfected cells. The receptor 
density was calculated to be about 1000 receptors per cell. In contrast, we found 5 times 
higher receptor density of mVPAC1 transfected cells, the Kd value for mVPAC1 was 
calculated to be around 2 nM. There was no specific binding seen in the control pIRES 
cells. Data analysis was done using the Easybound software. The curves were drawn by 
the software and cannot be manipulated. Further experiments tested whether the mVPAC 
receptors on the Jurkat T cells were functional. 
 
 
 
 
 
 58 
A.) 
 
B.)
pIRES
0
1000
2000
3000
4000
5000
6000
7000
1.E-13 1.E-12 1.E-11 1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05
Unlabeled VIP M
 
 
VPAC2
0
500
1000
1500
2000
2500
3000
3500
4000
1.E-13 1.E-12 1.E-11 1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05
Unlabeled VIP M
 
 
 
 
 
 
 
0         
0         
 59 
C.) 
VPAC1
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
1.E-13 1.E-12 1.E-11 1.E-10 1.E-09 1.E-08 1.E-07 1.E-06 1.E-05
Unlabeled VIP M
 
 
Figure 9: Competitive binding assays. Using A.) pIRES, B.) mVPAC2del_78, and C.) mVPAC1 
transfected Jurkat live cells binding assays were performed at room temperature. Shown data are 
representative of at least 3 independent experiments. Data analysis was done using the Easybound software. 
The curves were drawn by the software and cannot be manipulated. 
 
4.4 cAMP assay of human Jurkat T cell transfectants 
The intracellular signalling pathways mediating the actions of VIP and pituitary 
adenylate cyclase-activating polypeptide (PACAP) were investigated in these stable 
transfectant cell lines. A cAMP ELISA assay as described in the method section was 
applied. Two different stimuli at different concentrations in the bottom of the transwell 
chamber VIP and PACAP 38 were used. PACAP 38 is a member of the vasointestinal 
polypeptide/secretin/glucagon family. 
 
 
 
 
0         
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In accordance with the binding studies, ligand-dependant cAMP accumulation in 
mVPAC1 was observed, and to a lesser extent in mVPAC2del_78   stable Jurkat cells but 
not in control cells (Fig.10). A minimal increase in cAMP in control untransfected cells 
indicated that the surface expression of the endogenous hVPAC1 and hVPAC2 was very 
low. VIP was found to be as effective as PACAP-38 in inducing a cAMP response. 
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B.) 
PACAP38 Stimulated cAMP 
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Figure 10 A.) and B.): cAMP assay with human Jurkat transfectants. The transfectants 
were treated with various amounts of VIP (A) or PACAP38 (B) (concentration range 10-7 to 10-10 M). 
cAMPi was measured using an ELISA system purchased from R&D Systems. Each column and bar depicts 
the mean ± S.D. of the result of three studies conducted in duplicate. 
 
4.5 Starvation survival studies of human Jurkat transfectant 
Jurkat transfectants were cultured in their exponential growth phase in fresh media with 
various fetal bovine serum (FBS) concentrations and the kinetics of their density was 
studied. The cell density at the beginning was 106 cells/ml.  After 1 day of culture in 0% 
FBS there was a decrease in the cell density of all transfectants. The most dramatic 
decrease was seen in mVPAC2del_78 transfectants, which may indicate that these cells 
have become more dependent on certain growth factors. Such growth factor dependency 
appeared to be underlined by the increased proliferation of mVPAC2del_78 transfectants in 
10% FBS. On the other hand, the mVPAC1 cells appear to have become more 
independent of growth factors, which is reflected in their increased density compared 
with the pIRES transfected and mVPAC2del_78   cells in all studied FBS concentrations.  
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When grown in media containing FBS no further increase in cell density of pIRES 
transfectants was seen after 1 day, indicating that inhibitory factors may be present in 
FBS or produced by the pIRES transfectants that inhibit the proliferation. By day 2 and 4 
the proliferation of pIRES cells had increased, which may suggest the degradation of 
inhibitory factors or the production of Jurkat-specific growth factors.  
In conclusion it appears that mVPAC2del_78 was able to confer growth factor dependency, 
whereas mVPAC1 conferred growth factor independency to the Jurkat cells.  
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Figure 11: Cellular densities of Jurkat transfectants at different fetal bovine serum 
(FBS) concentrations and different days 1, 2 and 4. Jurkat transfectants were cultured in fresh 
media in triplicates and live cell numbers were determined by trypan blue exclusion. (p<0.05) 
 
4.6 Flow cytometry apoptosis study of human Jurkat T cell transfectants 
Dead cells that have a disrupted cellular membrane incorporate 7AAD as detected by 
flow cytometry (FACS). Jurkat transfectants were incubated at 106 cells/ml density in 
fresh media containing 10% FBS overnight and subsequently triplicates of cultured cells 
were stained with 7AAD and analyzed in FACS.  
The ratio of alive/dead cells was approximately twice that in mVPAC1 and 
mVPAC2del_78   transfectants as compared to pIRES control transfectants. This finding 
may indicate that the lower cell numbers in the previous experiment in pIRES cells might 
be at least to some extent due to increased cellular death. The observation that 
mVPAC2del_78   cells show even a slightly higher alive/dead ratio compared with 
mVPAC1 transfectants, but at the same time exhibit as shown in the previous section a 
lower cell density, indicates that mVPAC2del_78  transfectants proliferate less and undergo 
apoptosis or necrosis also less than the other studied cell types. 
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Figure 12: Flow cytometry. The ratio of alive/dead cells was measured by 7AAD staining and 
subsequent FACS analysis. At their logarithmic growth phases, the mVPAC1 and mVPAC2del_78 
transfectants show a higher ratio of alive/dead cell number. 
 
 
4.7 Migration study of human Jurkat T cell transfectants 
The chemotactic effects of VIP and human stromal derived factor-1 (hSDF-1) as positive 
controls were then studied on these human Jurkat T cell transfectants using a chamber 
transwell system. Previous studies had demonstrated that lymphocytes were able to 
migrate in the Boyden chamber assay when the polycarbonate filters were coated with 
matrix protein such as fibronectin (Kelvin et al., 1993). In this migration study, VIP (in 
different concentrations - data not shown) caused a significant reduction of migration in 
all three transfectant cell lines which reached significance in both mVPAC1 and 
mVPAC2del_78 Jurkat T cells, but not in the untransfected pIRES control cells. If VIP and 
hSDF-1 were added together as stimuli, migration decreased significantly in both the 
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mVPAC1 and pIRES controls, but to a lesser degree in mVPAC2del_78. If hSDF-1 was 
added alone, which is known to be a T cell migration stimulus, the best migration 
response from the mVAPC1 transfected cells, and the least response from the 
mVPAC2del_78 transfectants was seen. 
If no stimulus was added at all, a random cell migration, or chemokinesis response was 
seen in all three transfectant cell lines. Thus, the cells showed altered migration profiles.  
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Figure 13: Migration assay. VIP causes a significant reduction of Jurkat cell migration in mVPAC1 
and mVPAC2del_78 transfected cells but not in untransfected control cells (pIRES). VIP treatment of hSDF-
1 treated cells significantly inhibits migration of pIRES and mVPAC1 transfected cells but not of 
mVPAC2del_78 transfected cells. 
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5. Discussion 
At the time of the proposed studies, there had been no reports of splice variants of the 
mVPAC2 receptor. The receptor is thought to help control the T cell response in various 
settings. It was hypothesized that splice-variants of VPAC2 receptor may exist in murine 
tissues that act as an additional level of control to regulate function. 
These PCR based experiments have shown that a variant of mouse VPAC2 is present in 
mouse lung tissue. The resultant sequence showed a deletion of 26 amino acids from the 
first extracellular domain of the first transmembrane domain. The missing sequence is 
equivalent to, and appears to correspond to, virtually the entire fifth exon. Based on 
sequence analysis the resulting transcript could be translated, although a region of the 
extracellular and first transmembrane of the receptor would be missing. Functionally, the 
first transmembrane region is thought to be important for ligand binding and thus may be 
important in receptor mediated effects. To this end, signaling and migration studies were 
designed to characterize these issues more in detail using mouse VPAC1 and VPAC2 
GPCR stable transfectants in human Jurkat T cells. After several weeks of Geneticin-
selection of Jurkat T cells transfected with pIRESneo3-VPAC plasmids, stable 
transfectants were generated where the mRNAs encoding mouse VPAC1 and the mouse 
VPAC2 deletion-mutant were constitutively expressed.  
The presence of specific binding sites (transgenic expressed receptors) was demonstrated 
in the two cloned mouse VPAC receptor transfectant T cell lines using 125I -VIP as a 
radioligand. The receptor density of the mVPAC1 transfectant cells was five times higher 
than for the mVPAC2del_78  transfectant cells. The mVPAC1 Jurkat cells bound VIP with 
high affinity and mVPAC2del_78 with lower affinity. The respective mean Kd value of 
mVPAC1 was 2nM and of mVPAC2del_78 was 1-2 nM. There was no binding of the 
radioligand to untransfected Jurkat cells. These results demonstrated that any differences 
in signaling and transduction of functions between the two forms of mouse VPAC 
receptor could not be attributable to altered binding of VIP. Further experiments were 
applied to test whether the VPAC receptors on the Jurkat T cells were functional. 
Alternative splicing is a process of mRNA editing which changes the molecular (like 
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ligand affinity or regulation of intracellular signalling) and pharmacological properties of 
a receptor by changing its structure.  
Increase in cAMP 
 The regulation of cAMP levels is critical for diverse biologic processes in all cell types 
and is a feature of signal transduction from multiple receptors, including T cell receptors. 
One of the principal signals transduced by VIP binding to VPAC1 and VPAC2 is a Gαs-
mediated increase in [cAMP]i. In these studies, a 10-fold increase in the [cAMP]i in 
mVPAC1 transfectants were elicited by VIP in a concentration-dependent relationship up 
to a maximal level similar to that attained by PACAP 38. The deletion-mutant 
mVPAC2del_78 transfectants showed a much lower rise in [cAMP]i at different 
concentrations of VIP and PACAP 38 added. Untransfected Jurkat T cells that express 
only very low levels of human native VPAC1 and VPAC2 showed a very low raise in 
[cAMP]i, which never exceeded 10-fold . While cAMP clearly mimics the effect of VIP 
on the transfectants, additional messenger pathways may also be involved. The cAMP 
signal is often integrated with that of other signals, particularly Ca2+, that also regulate 
the activity of ACs and phosphodiesterases (Zaccolo and Pozzan, 2003). 
Studies on gene expression of VIP suggest a two way relationship between VIP and 
cAMP. VIP biosynthesis is promoted by higher cAMP levels, and thus the peptide is 
potentially capable of stimulating its own generation (Gozes and Brenneman, 1989). 
GPCRs use different Gs dependent intracellular signaling pathways. One of the effects 
seen is an increase in cAMP, which was also examined in this thesis. The importance of 
these G signaling pathways in the context of VPAC receptors stimulation is not fully 
understood.  Agonists for several GPCR’s have been shown to increase the levels of 
immunosuppressive cyclic AMP in immune cells. VIP has been found to stimulate 
adenylate cyclase in membrane preparations from both cultured and peripheral blood 
lymphocytes (O'Dorisio et al., 1981).  Other receptors associated with cAMP increase 
include prostaglandin E1 and E2 and the histamine receptors. These early studies 
suggested the potential role of cyclic AMP as an important second messenger in VIP 
action (Laburthe et al., 1994). 
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Every member of the group II family GPCR’s identified to date mediate a robust increase 
in cellular cAMP levels, presumably via receptor coupling to the heterotrimeric G protein 
Gs (Laburthe et al., 1996). The likely retraction and distortion of this extracellular 
domain by deletion of the amino acid sequence would be expected to alter signalling and 
function. Transfectants expressing the deletion-mutant VPAC2 GPCRs at a level equal to 
that of mVPAC1 GPCRs control transfectants failed to manifest VIP-evoked increases in 
[cAMP]i. 
Another published study using HEK 293 cells transiently transfected with rat VPAC1 
showed an EC50 for cAMP accumulation of 0.2 nM in response to VIP. In time-course 
experiments a rapid increase in cAMP accumulation was demonstrated that declined with 
a t1/2 of 5 min, yielding a complete cessation of further cAMP accumulation after 10-15 
min of agonist exposure. This dose dependent increase in cAMP was completely 
desensitized after 20 minutes (Shetzline et al., 2002). 
Subtypes of a given receptor can differ markedly in their desensitization properties and 
this may be an important reason for the existence of receptor subtypes. After activation 
many ligand-gated ion channels enter a desensitized state in which neurotransmitter like 
VIP remains bound but the ion channel is closed. An important process in the 
desensitization of GPCRs is the phosphorylation of agonist occupied receptors, followed 
by receptor internalization and, finally, eventual recycling to the plasma membrane as a 
competent receptor (Ferguson et al., 1998).  
Like most GPCRs, it has been demonstrated that hVPAC2 receptor is desensitized in 
response to VIP exposure. The receptor undergoes both agonist-induced phosphorylation 
and internalization and it is likely that both processes are involved in desensitization of 
the receptor (McDonald et al., 1998). Several different intracellular signaling pathways 
for VIP have been described (Pincus et al., 1990a). The cAMP pathway is an important 
pathway in T cell biology. Wang et al. studies indicate that VIP inhibits cytokine 
production in stimulated CD4+ T cells through two separate mechanisms, which involve 
both cAMP-dependent and cAMP-independent transduction pathways (Wang et al., 
1999). 
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VIP (1µM) elevates intracellular levels of cAMP four fold and causes secretion of BN-
like peptides from SCLC cells (Moody and Perry, 1990). VIP and PACAP-38 are 
equipotent in stimulating cyclic AMP production at the VPAC2 receptor (Lutz et al., 
1993). In this cAMP assays  the transfectants were treated with different VIP and 
PACAP-38 concentrations and we could see that VIP and PACAP-38 were equipotent in 
stimulating cAMP as described by Lutz et al. Interestingly, Ishihara and Zawilska saw a 
stronger action of PACAP-38 than of VIP. This may be explained in part by the different 
cell type model used (Ishihara et al., 1992; Zawilska et al., 2005).  
It has been suggested that cAMP can serve as a second messenger mediating the long-
term survival-promoting actions of VIP on sympathetic cultured neuroblasts (Pincus et 
al., 1990a).  To better define the effect of cAMP on survival, the authors cultured their 
cells in the presence of VIP or an analogue of cAMP (CPT). This lead to an increase in 
survival 6- and 10-fold respectively suggesting that cAMP may serve as a second 
messenger mediating the survival promoting actions of VIP on neuroblasts (Pincus et al., 
1990a).  These observations may help explain the apoptosis and starvation experiment 
results detailed in this thesis. 
Starvation survival studies of Jurkat transfectants 
Survival studies performed as described in the method section showed that in contrast to 
the mVPAC1 transfectants, mVPAC2del_78 transfectants and untransfected Jurkats need 
growth factor for their proliferation. MouseVPAC1 and mVPAC2del_78 transfectants 
reached higher cell densities as compared to the untransfected cells. To what extent 
VPAC expression may inhibit contact inhibition of proliferation in vivo will require 
further investigation. The data suggest that VPAC-like receptors may also be important in 
maintaining cellular mass of the immune compartment.  
The increased survival of mVPAC1 transfectants may also be associated with a decrease 
in the sensitivity of the cells to apoptosis. In the prostate cancer cell line PC-3 VIP and 
PACAP 27 were shown to modulate the expression levels of antiapoptotic and 
proapoptotic proteins in addition to inhibiting DNA fragmentation during apoptosis 
induced by serum withdrawal. This increased cell survival is thought to be exerted 
through VPAC1 (Gutierrez-Canas et al., 2003). Sumimoto described a mechanism that 
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could explain the survival effect exerted by G-protein-coupled receptor agonists, such as 
bombesin and endothelin-1. (Sumitomo et al., 2001) They observed that these 
neuropeptides stimulate ligand-independent activation of the IGF-1 receptor resulting in 
activation of the serine-threonin kinase Akt that mediates cell survival. 
Cultured cerebellar granule cells undergo apoptosis within 48 hours in the absence of 
fetal calf serum (FCS). The addition of VIP, PACAP38 and PACAP27 dose dependently 
rescued cells from apoptosis, but only VIP was found to be effective at 10-6 M (Canonico 
et al., 1996). Neuroprotective actions of cAMP in various cell types have been reported 
(Brenneman et al., 1985; Kaiser and Lipton, 1990; Rydell et al., 1988). VIP, acting by 
increasing cAMP, has a neurotrophic effect on electrically blocked retinal ganglion cells 
and may be an endogenous factor modulating normal cell death in the retina (Kaiser and 
Lipton, 1990). 
VIP has been shown to prevent PC12 cell death during serum withdrawal. Cell viability 
was assessed with varying concentrations of VIP (Said and Dickman, 2000). VIP has also 
been characterized as a growth regulator for fetuses (Gressens et al., 1993; Waschek, 
1995) and during embryonic brain development (Gozes et al., 1999). 
The stimulation of protein kinase A, protein kinase C, and MAP kinase leads to activation 
by phosphorylation of the cyclic (c)AMP-response-element-binding protein (CREB). The 
latter step results in upregulation of anti-apoptotic bcl-2. We now have evidence 
supporting the importance of protein kinase A (PKA) in the protection afforded by VIP 
paraquat-induced injury. Lung edema was prevented by VIP, and PKA inhibitor H89 
blocked the protection by VIP, but protein kinase C (PKC) inhibitor had little effect 
(Pakbaz et al., 1993). 
The other components of this integrated view of survival-promoting pathways in the lung 
remain to be validated. VIP was found to increase the survival of neurons and prevents 
the neurotoxic effect of HIV (Pincus et al., 1990b). VIP protects mouse and human 
thymocytes treated with cytolytic dose of the prednisolone in vitro (Ernstrom et al., 
1995). 
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Apoptosis study of human Jurkat T cell transfectants 
Apoptosis, or programmed cell death, is essential for normal tissue development and 
homeostasis, and also represents a critical mechanism of pathologic cell death (Fraser and 
Evan, 1996).  Increases in cAMP may either initiate or inhibit apoptosis of lymphocytes 
depending on the specific circumstances (Goetzl et al., 1995a). Increasing evidence 
suggests that VIP also plays a role in cell survival in different systems. In fact, VIP has 
been shown to stimulate neuronal survival directly and indirectly via the glial cell release 
of neurothrophic factors (Brenneman et al., 1997). Largely as a result of research on 
neuronal cells, a hypothesis has been presented of the signal transduction pathways that 
promote cell survival through VIP (Walton and Dragunow, 2000). 
In the experiments detailed here flow cytometry based assays were used to assess 
apoptosis of the mVPAC1 and mVPAC2del_78 transfectants.  Both lines were found to 
undergo less apoptosis as compared to the control cells. In addition it was observed that 
the mVPAC2del_78 transfectants showed an even slightly higher alive/dead ratio as 
compared to mVPAC1 transfectants, but at the same time exhibit a lower cell density. 
This suggests that mVPAC2del_78 transfectants undergo less apoptosis than do the other 
two cell types. The observation that mVPAC2del_78 cells show a slightly higher alive/dead 
ratio as compared to the mVPAC1 transfectants, but at the same time exhibit, as shown in 
the previous section a lower cell density, suggests that mVPAC2del_78 transfectants 
proliferate less and undergo apoptosis or necrosis also less than the other studied cell 
types. Most of the published data did not show a decrease of apoptosis through VPAC2 
receptor as seen in our experiments.  
Prevention of apoptosis by VPAC1 and VPAC2 receptors has been shown by previous 
experiments. VIP and PACAP were found to prevent apoptosis through both mVPAC1 
and mVPAC2 receptors in stimulated T cells as shown by Delgado (Delgado and Ganea, 
2000). The effect of VIP, PACAP27 and PACAP38 (in a concentration range from 10-13 
to 10-6 mol/l) on glucocorticoid induced apoptosis in vitro on thymocytes was studied. 
VIP and PACAPs were both found to inhibit apoptosis significantly, and increase the cell 
survival of thymocytes through stimulation of the VPAC1 receptor (Delgado et al., 
 72 
1996a). VIP and PACAP was also shown to prevent apoptosis in stimulated T cells 
through both mVPAC1 and mVPAC2 receptors (Delgado and Ganea, 2000).    
VIP has shown to stimulate neuronal survival directly and indirectly via glial cell release 
of neurotrophic factors (Brenneman et al., 1997).  Here the Jurkat cells were not 
activated.  Indeed, the Jurkat cell line represents a late thymic early peripheral blood T 
cell phenotype.   
Exogenously added VIP has also been shown to prevent apoptosis of primary cultures of 
mouse cerebellar granule cells under nondepolarizing conditions, the effect was mediated 
specifically through the VPAC1 receptor (Fukuchi et al., 2004). 
Effects on Migration 
VIP caused significant inhibition of chemotactic migration in both mVPAC1 and 
mVPAC2del_78 Jurkat T cells but not in control cells. It is possible that the endogenous 
hVAPC1 is not expressed at high enough levels, although we were able to amplify and 
sequence the full-length transcript in control Jurkat cells (we could not detect the full-
length hVPAC2 in Jurkat cells). The relative non-responsiveness of mVPAC2del_78 
transfectants to VIP may be due in part to transcript modification or to its distinct 
biologic activity. When the chemokine hSDF-1 was used alone (which is known to be a T 
cell migration stimulus over the CXCR4 receptor) the best migration response was seen 
from the mVAPC1 transfected cells. If both VIP and hSDF-1 were added together as 
stimulus, the migration was found to decrease significantly in both mVPAC1 and control 
cells, but to a lesser degree in mVPAC2del_78 suggesting a functional cross desensitization 
by the two different chemotactic signals and confirm that VIP can act as a chemotactic 
inhibitor in our model. 
In migration assays, the mVPAC1 and mVPAC2del_78 transfectants showed a distinct 
behavior that was not dependent on stimulation with the known ligands. Under the 
conditions chosen for the migration assays there should be no known VPAC ligands 
present in the media. Nevertheless, mVPAC1 and mVPAC2del_78 transfectants appeared 
to show a greater ability to migrate through a collagen coated synthetic membrane with a 
pore size of 5 micrometers. In addition, their response to the S1P stimulus appeared more 
pronounced when compared with control cells. These data may indicate that the 
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availability of the classical ligands may not be obligate for biologic activity of the VPAC 
receptors.  
Moore has studied the effect of VIP on the passage of cells out of popliteal lymph nodes. 
In accordance to our results, his results also suggested that VIP may inhibit egress of 
small lymphocytes (Moore, 1984). 
In contrast to what was described by Dunzendorfer who demonstrated that VPAC1 
receptor was responsible of migration of human eosinophils, and could show a clear 
migration response induced by VIP, we could not see this migration response in our 
Jurkat T cell transfectants. Thus different cell types might show a different migration 
response induced by VIP (Dunzendorfer et al., 1998). 
VIP is a known immunosuppressive neurotransmitter. Grimm also showed that VIP could 
inhibit the function of chemokine receptors on human monocytes and T-lymphocytes 
leading to impaired chemotaxis and calcium flux in the response to the cognate 
chemokine ligands CXCL12, CCL3, CCL4 and CCL5.  This was mediated through 
VPAC1 receptor and was not caused by chemokine receptor internalization. Chemokines 
are key mediators of leukocytes chemotaxis to inflammatory sites in for example 
rheumatoid arthritis (Grimm et al., 2003). 
Different VIP concentration were assessed in a dose response analysis (data not shown) 
Taub had shown that lymphocytes optimally respond at 10-8 to 10-9 M, displaying no 
significant migration at concentrations less than 10-11 M or greater than 10-6 M (Taub et 
al., 1993). One potential mechanism that could explain these results is that homologous 
desensitization of the VPAC receptors by the ligand results in rapid receptor 
internalization from the cell surface. Inhibition of  receptor function caused by binding of 
ligands to different receptors (heterologous desensitization) usually results from 
activation of kinases such as protein kinase C (Ali et al., 1993). 
The homing of mouse lymphocytes to mesenteric lymph nodes and Peyers patch of 
recipient mice was inhibited by ex vivo treatment of T cells with VIP, is associated with 
the inhibition of VIP receptor expression (Ottaway, 1987). So in this model, the VPAC 
receptor expression may have also been inhibited as explained by the lack of migration 
response. 
 74 
Other studies have shown that VIP has no effect on stimulated T cells, so in some way 
the Jurkat T cells transfectants have been stimulated and the levels of receptor expression 
went down in our study. In T cells, cAMP-dependent protein kinase type I co localizes 
with the T cell receptor-CD3 complex (TCR/CD3) and inhibits T cell function (Skalhegg 
et al., 1994). 
Other publications have shown that VIP has potent chemotactic effects at concentrations 
between 10-8 and 10-9 M on human T lymphocytes and monocytes (Johnston et al., 1994). 
VIP is even as potent as chemokines RANTES and MIP-1α, but showing a reduced 
response at higher concentration (Wang et al., 1993). If the neuropeptide VIP is at too 
high a concentration, the T cells may become desensitized, similar to the response 
observed with other chemotactic ligands (Samanta et al., 1990). Previous studies, have 
demonstrated that VIP treatment can alter murine T cell homing (Lopez-Gonzalez et al., 
1992).  
 
Limitation of the studies: 
As a critical issue I must address the generally low expression level of human VPAC2 
receptor and human VPAC1 receptor in the Jurkat T cells and the potential influence of 
this on the presented results. The mouse lung expresses high amounts of VPAC2 
receptors, presumably located in the epithelium; the human lung expresses predominantly 
VPAC1 receptors, although VPAC2 mRNA was also identified in one study (Harmar, 
2003).  Further investigation needs to identify species differences in the expression of the 
VPAC2 receptor deletion variants and to locate VPAC2 receptor mRNA, which may not 
be translated into a functional protein with equal efficiency in all tissues. It remains to be 
seen whether the mVPAC2del_78 receptor splice variant is able to couple to the 
IP3/[Ca2+]I pathway. It was previously shown that VAPC1 and VPAC2 receptor are also 
able to couple IP3/[Ca2+]I pathway (Langer et al., 2001). 
During the cAMP experiments forskolin was not used. Forskolin is a VPAC2 selective 
agonist or VPAC1-selective agonist, and serves as a positive control. It is known to 
increase [cAMP]i. Such experiments were previously described (Grinninger et al., 2004), 
thus I should have set up additional experiments were I added a VPAC1 antagonist and 
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agonist Ro 25-1553 to see if the inhibitory effect through VPAC1R could be prevented 
by pretreatment of the antagonist as shown by Grimm (Grimm et al., 2003). 
The polycarbonate filter assays used in these studies have several limitations. The main 
drawback of these filters is that the thickness of the 10 µm membrane which does not 
allow any assessment of effects of absolute concentration compared to gradients 
(Wilkinson, 1996). 
 
Conclusions 
The important questions that remain to be elucidated about the deletion-variant 
mVPAC2del_78 GPCR include the mechanism of its generation, its cell and tissue 
distribution, determinants controlling the regulation of its expression during development 
and after cellular activation, and its natural functional role in immunity and other 
physiological, pathophysiological activities affected by the VIP-VPAC2 GPCR axis. For 
example, what can be learned about its coupling to signal transduction pathways leading 
to differences in the level of activation of adenylate cyclase and phospholipase C? 
Synthetic VIP receptor antagonists inhibit the proliferation and potentiate the ability of 
chemotherapeutic agents to cause apoptosis of lung and breast cancer cells. VIP-
chemotherapeutic conjugates have been synthesized which bind to VPAC1 receptors and 
are internalized, resulting in the killing of lung and breast cancer cells. These results 
suggest that VPAC receptors may be molecular targets for diagnosis, prevention and 
treatment of breast cancer as well as lung cancer (Moody and Gozes, 2007). One could 
also speculate that VIP-stimulated T cells can signal to other T cells as neurons through 
soluble factors such as chemokines that regulate than T cell activity. 
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7. Abbreviations 
 
7-AAD 7-Amino-actinomycin D 
AC Adenylyl cyclase 
ATP adenosine triphosphate 
Bp base pair 
ºC grad celsius 
Ca  Calcium 
CaM, calmodulin 
cAMP cyclic adenosine monophosphate 
cDNA complement desoxyribonucleinacid  
CHO chinese hamster ovary 
CNS central nervous system  
Cpm counts per minute 
CREB cAMP response element binding protein 
DAG diacyl glycerol 
DEPC Diethylpyrocarbonate 
DNase desoxyribonuclease  
EC extracellular  
E.coli Escherichia coli 
EDTA Ethylendiamintetraacetat 
ELISA enzyme-linked immuno-absorbent assay 
ER  endoplasmatisches reticulum 
FACS fluorescence-activated cell scanning 
FBS fetal bovine serum 
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G gramm 
GDP guanosine diphosphate 
GEF guanine nucleotide exchange factor 
GPCR G-protein coupled receptor 
GTP guanosine triphosphate 
IC intracellular 
Ins (1,4,5) P3, inositol 1,4,5-trisphosphate 
kDa kilodalton 
min minute 
ml milliliter 
MMP matrixmetalloproteinase 
Mw molecular weight 
Nt nucleotide 
PAC  pituitary adenylate 
PACAP Pituitary Adenylate Cyclase-Activating Polypeptide 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pIRES primary internal ribosomal entry side 
PIP2  phosphatidyl inositol 4,5-bisphosphate 
PKA Proteinkinase A 
PKC, protein kinase C 
PLC Phospholipase C 
PLD  phosholipase D 
RA  Rheumatoid arthritis 
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RNA Ribonucleic acid  
hSDF-1 human stromal-derived factor-1 
TBE TRIS-Borat-EDTA-Puffer 
TM Transmembrane  
µg microgram 
UCSF University of California San Francisco 
V Volt 
VIP  Vasoactive intestinal peptide 
VPACR Vasoactive intestinal peptide receptor  
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